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Role of the Ang-Tie2 pathway in the invasive recurrence of GBM following anti-
VEGF therapy 
by 
Nahir Cortés Santiago 
Supervisory Professor: Candelaria Gómez-Manzano, M.D. 
 
 Strong pre-clinical and clinical data supporting the effectiveness of bevacizumab, 
a humanized monoclonal anti-VEGF antibody, for the treatment of gliomas led to its 
accelerated approval for the treatment of patients with recurrent glioma.  However, 
despite strong anti-tumor effects, upon treatment with bevacizumab, patients will 
invariably recur with a tumor characterized by enhanced invasiveness and resistance to 
therapy.  This study aims to elucidate the mechanisms leading to this enhanced 
malignancy with the hope of uncovering new potential therapeutic targets for combined 
treatment.  Using tissue sections from U87-derived glioma bearing mice treated with or 
without aflibercept (another anti-VEGF antibody) we have gathered evidence of a 
significant increase in the number of Tie2 expressing monocytes (TEMs) within the 
tumor after treatment, particularly around areas of invasion. TEMs are a pro-angiogenic 
subset of circulating monocytes that express the Tie2 receptor. Our data demonstrates 
that TEMs have higher expression and activity of pro-invasive molecules, such as MMP2 
and MMP9, than their Tie2 negative counterparts and are able to increase glioma cell 
invasion in vitro, suggesting an active role of these cells in the invasive process observed 
after treatment.  Furthermore, we have shown that expression of angiopoietin 2 (Ang2), a 
Tie2 ligand, is dramatically increased in the periphery of the tumor after aflibercept 
 vii 
treatment. Interestingly, our data provides evidence that Ang2 is chemoattractant to 
TEMs, both in vitro and in vivo suggesting a potential mechanism of recruitment of these 
cells to the tumor. These data suggests an active role of the Ang-Tie2 pathway, and in 
particular Ang2, in the invasive recurrence of GBM following anti-VEGF therapy and 
that targeting it in combination with anti-VEGF therapy could lead to improved 
outcomes.  Supporting this idea, we were able to observe a dramatic decrease in the 
invasive phenotype after anti-VEGF treatment when we inhibited the Ang-Tie2 pathway 
in combination with an anti-VEGFR antibody.  These results have important implications 
for patients with GBM since a decrease in the invasive pattern upon recurrence after anti-
angiogenesis therapy could potentially render the tumors amenable to surgical excision 
upon recurrence.  This in turn can lead to improved patient survival. 
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Chapter I: Background information and significance 
 
I. Glioblastoma 
Glioblastoma (GB) is the most common and aggressive (grade IV) primary brain 
malignancy in adults. Despite therapeutic advances within the last ten years, patients 
diagnosed with GB have a grim prognosis with median survival ranging between15-18 
months and a 5 year survival rate of less than 5%.1-2    Even with aggressive therapy with 
the standard of care, which consists of maximal surgical resection coupled with 
radiotherapy and chemotherapy with temozolomide, GB patients inevitably present with 
recurrent disease.3 
Pathologically, it is characterized by extensive necrosis and microvascular 
proliferation, which makes them highly vascular tumors.2 One of the most important 
mechanisms through which these tumors acquire such prominent vascularity is through 
activation of hypoxia inducible factor (HIF) which drives the expression of vascular 
endothelial growth factor (VEGF).4 Along this line, bevacizumab, an anti-VEGF 
antibody, was recently granted accelerated approval by the FDA for the treatment of 
recurrent GB due to unprecedented results in clinical trials.5-6 
 
II. Angiogenesis 
The generation of stable, functional blood vessels and vascular networks is an 
essential biological process, without which complex organisms such as ourselves could 
not exist.  To date, two main processes through which this can occur have been 
described: vasculogenesis, which is the process of de novo vessel formation from 
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endothelial precursors, and angiogenesis, which is the formation of new blood vessels 
from pre-existing ones.7 Vasculogenesis mainly occurs during embryogenesis, in which a 
primitive vascular network is established from endothelial precursor cells named 
angioblasts.7  Following this initial step, angiogenesis takes over and allows for the 
ramification of this primitive vascular network and establishment of complex vascular 
networks that deliver nutrients and oxygen throughout the human body.7 In healthy 
adults, most vasculature is quiescent, and angiogenic processes are circumscribed to 
organ systems in which vascular remodeling is essential for its function (i.e. female 
reproductive tract) or for the purposes of wound healing.8  However, pathological 
angiogenesis has been described for several disease processes (i.e. inflammatory disease 
states, cancer) and the role of active angiogenesis in tumor development has been 
extensively studied (see below).8 
 
The VEGF-VEGFR pathway in angiogenesis 
The establishment of new functional blood vessels is a complex multistep process.  
Physiological stimuli, such as hypoxia, initiate this process mainly through upregulation 
of vascular endothelial growth factor (VEGF).  VEGF, was initially described and 
purified as a tumor secreted factor capable of inducing vascular permeability and was 
therefore named vascular permeability factor (VPF).9 Several years after, Leung et al. 
independently reported the discovery of vascular endothelial growth factor, a potent 
endothelial cell mitogen capable of inducing angiogenesis.10 VPF and VEGF were 
described to be the same molecule by Keck et al. shortly after the discovery of VEGF.11  
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The VEGF family is composed of five ligands, namely VEGF-A (from now on 
referred to as VEGF), VEGF-B, VEGF-C, VEGF-D and placental growth factor.  VEGF-
A mRNA can be alternatively spliced to produce four main different isoforms: VEGF121, 
VEGF165, VEGF189 and VEGF206.12-13 Three tyrosine kinase receptors have been 
described so far, namely VEGFR1, VEGFR2 and VEGFR3 with other co-receptors 
described such as neuropilins.  Evidence gathered so far demonstrate that VEGFR2 is the 
most important mediator of endothelial cell responses to VEGF and therefore therapeutic 
approaches aimed at targeting the receptor are directed against VEGFR2.14-15  
As described above, VEGF is a potent mitogen and pro-survival molecule for 
endothelial cells.  Its expression is upregulated by environmental stimuli such as hypoxia 
and upon binding to VEGFR leads to endothelial cell proliferation and migration, two 
key events without which angiogenesis cannot occur.8 Hypoxia also leads to increased 
matrix metalloproteinase (MMP) expression, such as MMP9, which degrade the 
extracellular matrix (ECM) around the cell.  This has a dual effect: releasing VEGF 
bound to ECM making it available for interaction with its receptor and degrading the 
ECM providing a path for endothelial cell migration.8  In parallel to VEGF upregulation, 
loosening of pericyte/endothelial cell interactions occurs mainly through the activity of 
angiopoietin 2 (Ang2), a Tie2 ligand (see below).  This “uncovers” endothelial cells 
causing them to become more sensitive to VEGF.  In the presence of high VEGF levels, 
endothelial cells begin to proliferate and migrate forming a cell column that eventually 
fuses forming a lumen through which blood can flow.  Elongation of this tubular 
structure occurs through endothelial cell proliferation and migration in response to a 
VEGF gradient and continues to occur as long as the pro-angiogenic stimuli are present.  
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Eventually, pericyte cells are recruited, and pericyte/endothelial cell interactions are 
established leading to the formation of a functional new vessel.16 The Ang-Tie2 pathway 
plays an essential role in this process (see below). 
 
The Ang-Tie2 pathway 
The Ang-Tie2 pathway is extremely important for normal blood vessel 
physiology.  It is composed of two type I tyrosine kinase receptors, namely Tie1 and 
Tie2. Tie2 was initially described by Dumont et al. as an endothelial cell specific orphan 
receptor.17 This changed in the following years, with the discovery of its currently known 
ligands, the angiopoietins (Ang).18-20  The importance of the Tie2 receptor in the vascular 
system was highlighted by loss of function studies that showed that lack of Tie2 led to 
embryonic lethality at E10.5 to E12.5.  These mice were unable to form a vascular 
network beyond the primary capillary plexus.   These early vessels failed to mature and 
showed fewer endothelial cells and diminished branching, as well as decreased pericyte 
and smooth muscle cell coverage.21-22 Consistently, gain of function studies in which 
Ang1, the main Tie2 agonist (see below), led to opposite changes.  Overexpression of 
Ang1 in skin led to numerous blood vessels that were highly branched, with decreased 
intrinsic, or induced, leakiness due to enhanced supporting cell coverage (pericytes and 
smooth muscle cells).23-24 
The ligands of the Tie2 receptor are referred to as angiopoietins.  There are three 
human angiopoietins (Ang), namely Ang1, Ang2 and Ang4 (Ang3 is an Ang4 mouse 
ortholog).18-20 Ang1 and Ang2 are the most widely studied human Tie2 ligands.  Ang1 is 
considered to be the main Tie2 agonist and as such, loss of function studies led to similar 
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outcomes as knockdown of Tie2.25 Upon binding to Tie2, it leads to dimerization or 
multimerization, and auto-phosphorylation of tyrosine residues located in the intracellular 
domain of the receptor.  This leads to binding and activation of downstream targets 
ultimately leading to endothelial cell survival and vessel stability.26 Tie2 and Ang1 are 
widely expressed in the adult vasculature and are required for the maintenance of a 
functional quiescent vascular network.8   
Ang2 is considered to be a natural Ang1 antagonist.  This notion came from gain 
of function studies in which mice engineered to overexpress Ang2 had similar vascular 
defects as mice deficient for Ang1.19 Further evidence of its antagonistic functions came 
later when mice with conditional overexpression of Ang2 were shown to be unable to 
phosphorylate Tie2, the idea being that when Ang2 is present it binds to the Tie2 receptor 
effectively preventing binding of Ang1.27  This in turn leads to loosening of pericyte 
coverage and vessel destabilization.  The end result of Ang2 activity on vascular 
structures will largely depend on the presence or absence of VEGF.  Loosening of 
pericyte coverage sensitizes endothelial cells to the effects of VEGF, and therefore, in the 
context of high VEGF expression, Ang2 potentiates its effects and functions as a pro-
angiogenic molecule leading to enhanced endothelial cell migration and sprouting.  On 
the other hand, in the absence of the pro-survival and mitogenic stimuli conferred by 
VEGF, lack of pericyte coverage causes endothelial cells to undergo apoptotic cell death.  
In this context, high Ang2 expression leads to vessel regression.28 Interestingly, the role 
of Ang2 in the Ang-Tie2 pathway has proven to be complex and in the absence of Ang1, 
Ang2 has been shown to partially activate the Tie2 receptor.29 Furthermore, Ang1 has 
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been shown to reverse the effects of Ang2 inhibition in colon, prostate and epidermoid 
carcinomas, suggesting Ang2 can function as a Tie2 agonist under certain conditions.30 
There are other roles of the Ang-Tie2 pathway outside blood vessel physiology 
and pathology.  For example, loss-of-function studies have shed light into other 
physiological roles for Ang2.  Although normal embryonic development is not hampered 
by lack of Ang2, mice with knocked down Ang2 expression develop chylous ascites that 
is lethal in the 129/J genetic background.31 This result suggests an important agonistic 
role of Ang2 in the development of lymphatic vasculature.  Furthermore, mice deficient 
for Ang2 are incapable of mounting a rapid inflammatory reaction in response to TNF-α, 
suggesting a key role for this cytokine in inflammation.  In depth studies on how Ang2 is 
capable of regulating the inflammatory response have shown that late stages of leukocyte 
recruitment, which involve firm adhesion and transmigration are affected by the absence 
of Ang2, whereas initial stages, namely chemoattraction and selectin-mediated rolling 
and tethering, are not affected.32 The Ang-Tie2 system has also been shown to be crucial 
for the maintenance of the hematopoeitc stem cell (HSC) niche.  HSC expressing the 
Tie2 receptor were found to be a side population within the bone marrow with a 
quiescent phenotype and anti-apoptotic features.  Osteoblasts and stromal cells within the 
bone marrow produce Ang1 that binds to and activates Tie2 within HSC in a paracrine 
manner.  This constitutive activation of the Ang-Tie2 pathway has been shown to be 
essential for maintenance and repopulation of the stem cell niche within the bone 
marrow.33 Finally, Ang1 has neuro-protective effects through inhibition of apoptotic cell 
death in neurons.  Whether the latter is mediated by Tie2 still needs to be clarified.34   
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Angiogenesis in cancer 
Angiogenesis is a highly complex process requiring a tightly regulated interplay 
of many molecular pathways, both pro- and anti-angiogenic.  An imbalance towards 
either one of the extremes of the spectra can lead to dysfunctional vasculogenesis and 
angiogenesis.  For example, genetic knockdown of even one VEGF allele leads to early 
embryonic death due to abnormal vasculature formation.35 On the other hand, a pro-
angiogenic environment lacking appropriate regulation can lead to disease, cancer being 
an example of the latter.8 The effective generation of a vascular network is considered to 
be a rate-limiting step in tumor progression.  The growth of any solid mass beyond a few 
millimeters requires the concomitant formation of blood vessels that allow oxygen and 
nutrient delivery to tumor cells, as well as waste removal from the tumor bed.36   
Tumor progression has historically been described in two major phases, namely 
avascular and vascular.  The avascular phase of tumor growth is characterized by the 
acquisition and accumulation of genetic alterations that confer a given cell a proliferative 
and survival advantage.  This leads to uncontrolled cell proliferation and the resulting 
formation of a small lesion.  Eventually, the lack of blood supply to central areas of the 
tumor hampers expansion and the mass reaches a point where apoptosis equals cell 
proliferation and no further growth occurs.37-38 In the absence of angiogenesis, these 
lesions can remain dormant for years and cause no disease.  Underlining the importance 
of vascular formation to generate a clinically significant tumoral lesion, there have been 
reports of accidental findings of small, occult lesions in autopsies from patients that died 
from a different cause.39  This supports the idea that only a subset of tumors eventually 
enters the second, vascular phase in which exponential tumor growth occurs.  Although 
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extensive research on the subject has shed some light into the mechanisms underlying 
this “angiogenic switch”, the subject remains obscure. 
Angiogenesis is the main mechanism through which tumors acquire a vascular 
network.  However, some solid tumors have been shown to induce de novo vessel 
formation through the recruitment of endothelial precursor cells from the bone marrow, a 
process called vasculogenesis.40 Adding to the complexity of tumor vascularity, cancer 
cells have been shown to integrate in the vessel wall.41 Similar to physiologic 
angiogenesis, initiation of tumor angiogenesis can be triggered by the sole overexpression 
of VEGF.  However, the imbalance of pro- and anti-angiogenic stimuli within the tumor 
microenvironment leads to the formation of chaotic vascular networks, with deregulated 
maturation and diminished or absent pericyte coverage.42 This leads to vessels containing 
features of capillaries, venules and arterioles altogether.  Lack of pericyte coverage leads 
to enhanced sensitivity to VEGF stimulation, which generates a vicious cycle of ongoing 
angiogenesis and the production of dilated leaky vessels that differ in great extent to their 
normal counterparts. 
 
III. Anti-angiogenesis therapy: development and challenges 
The idea that targeting angiogenesis for cancer treatment could be useful was first 
proposed by Judah Folkman in 1971.43 The discovery of VEGF and the understanding of 
its essential role in angiogenesis provided the basis for the development of several types 
of inhibitors of this pathway to target angiogenesis.  Antibodies against VEGF and its 
receptor (VEGFR), tyrosine kinase inhibitors with selectivity towards VEGFR and 
soluble VEGFR formulations have been developed, and in some cases FDA approved, for 
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the treatment of disease, including cancer.  The idea behind these efforts being that 
without an active VEGF pathway, angiogenesis cannot occur and tumors would “starve” 
to death.   
Bevacizumab, one of the currently FDA approved anti-angiogenesis agents, is a 
humanized monoclonal antibody that binds vascular endothelial growth factor and traps it 
in the circulation preventing it from interacting with the VEGF receptor (VEGFR).  Its 
precursor, a murine monoclonal antibody (muMAb 4.6.1) was developed by Kim et al. in 
an attempt to better understand the physiological roles of VEGF shortly after its 
discovery.44  It was shown to bind and effectively inhibit VEGF-mediated endothelial cell 
proliferation and vascular permeability.  A year later, the same group published a study 
demonstrating that VEGF induced angiogenesis in vivo and that targeting VEGF in vivo 
with mAB 4.6.1 led to decreased vessel density and inhibition of tumor growth in three 
tumor models: leiomyosarcoma, GBM and rhabdomyosarcoma.45 This was the first study 
to demonstrate that targeting VEGF in vivo led to decreased angiogenesis and tumor 
growth inhibition, establishing a precedent for further drug development.  Even though 
the biggest attention was given to the potential of targeting VEGF in cancer, this strategy 
was also investigated in other models of disease.  For example, diabetic retinopathy is 
characterized by hypervascularization of the retina, and studies were able to show that 
targeting VEGF in this context led to diminished vessel density in models of this 
disease.46 Furthermore, rheumatoid arthritis also has a prominent vascular component and 
some studies suggested that inhibiting VEGF in this context could be useful.47   
In 1997, five years after its development, Presta et al. published the humanization 
of mAb 4.6.1, now named bevacizumab.48   Bevacizumab had similar binding affinities to 
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VEGF, as well as tumor growth inhibitory properties as those observed for mAb 4.6.1.  
With this, a tool for testing the effectiveness of targeting VEGF in human disease was 
established.  The first placebo controlled trial was published by Yang et al.49 Patients with 
metastatic renal carcinoma were given placebo, low-dose bevacizumab or high dose 
bevacizumab.  Primary end points were time to progression of disease and response rate, 
with overall survival being a secondary endpoint.  Results demonstrated a significant 
increase in progression free survival, particularly in the high-dose bevacizumab group 
when compared with placebo.  No change in overall survival was observed.  Since then, 
many clinical trials have been conducted in several types of solid tumors leading to the 
approval of bevacizumab for the treatment of non-small cell lung carcinoma, metastatic 
colorectal and renal cell carcinoma and, of particular interest to us, second line treatment 
for GBM. 
The first report on the use of bevacizumab in GBM was done by Stark-Vance and 
was presented as an abstract at the 2005 European Association of Neuro-Oncology.50 She 
treated 11 patients who had recurrent GBM with 5mg/kg of bevacizumab combined with 
125mg/m2 irinotecan (CPT-11) and was able to show anti-tumor activity.  This opened 
the door for clinical trials with bevacizumab for the treatment of recurrent GBM.  
Historically, patients treated with conventional therapy had radiographic responses of 9% 
and 6-month progression free survival ranging between 9-15%.  Clinical trials performed 
with bevacizumab demonstrated an improvement of both these measures, producing 
radiographic responses ranging between 24-57% and 6-month PFS of 25-65%.  
Furthermore, its vascular normalization effects led to decreased cerebral edema and 
intracranial pressure, which resulted in a decrease in corticosteroid use in these patients 
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and a consequent improvement in quality of life.51 The FDA granted accelerated approval 
of bevacizumab in 2009 for the treatment of recurrent GBM due to the outcomes reported 
on clinical trials5-6 and it is currently standard of care for this patient population. Data on 
overall survival (OS), the most important parameter used to evaluate therapeutic efficacy, 
is not available for recurrent GBM.  However, two recent phase III clinical trials in which 
the efficacy of bevacizumab as a first line agent for GBM was evaluated concluded that 
bevacizumab did not lead to increased OS when compared to conventional therapy.52-53 
Whether this translates to the setting of recurrent GBM is undetermined since no large-
scale clinical trial with OS as a primary endpoint has been done for bevacizumab in this 
context. Importantly, progression free survival was improved in both studies, although 
the pre-specified improvement target was not achieved in one of them.53 
Even though bevacizumab led to an improvement in quality of life, progression 
free survival and radiographic responses in GBM, the idea of it being a miracle drug is 
far from reality.  Despite its benefits, patients treated with bevacizumab invariably 
present with recurrent disease and upon recurrence, the tumors acquire a highly invasive 
phenotype that is resistant to all currently available therapies.  At this point, prognosis is 
measured in short weeks.  The notion that bevacizumab treatment leads to enhanced 
invasion in gliomas dates to the year 2000, way before it was tested in the clinic and 
many years before its approval for the treatment of recurrent GBM.  Rubenstein et al. 
reported the use of bevacizumab for the treatment of intracranial glioma for the first time 
in an animal model.54 They demonstrated the effectiveness of bevacizumab at increasing 
survival, decreasing vessel density and increasing apoptosis of intracranial glioma, and 
discuss the infiltrative behavior of the tumor upon recurrence as an adaptation to anti-
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angiogenic therapy.  Since then, concerns regarding this highly aggressive and infiltrative 
behavior after anti-VEGF therapy has been raised in several studies, both in animal 
models as well as in patients.55-56 Evidence gathered demonstrated that targeting either 
VEGF or VEGFR led to similar outcomes, suggesting that this phenomena was a result of 
targeting the pathway, and did not necessarily stem from the approach taken to do so 
(targeting VEGF or VEGFR).  In 2009, Paez-Ribes et al. established the unequivocal link 
between inhibiting VEGF and highly aggressive and infiltrative behavior.55 In their study, 
they demonstrated that both, pharmacological inhibition of the VEGF pathway as well as 
genetic knockdown of VEGF, led to tumor progression with increased vessel cooption 
and enhanced invasion in a GBM model and pancreatic neuroendocrine carcinoma 
model, the latter having higher rates of distant metastasis in the context of VEGF 
inhibition.  Understanding how the tumors acquire this invasive and resistant phenotype 
following anti-VEGF therapy will be essential for improving GBM treatment and 
outcomes. 
 
IV. The tumor microenvironment 
Historically, research on cancer has focused on understanding the events 
occurring within tumor cells for tumorigenesis to take place.  Intensive efforts led to the 
identification of mutational events required for an epithelial cell to be transformed and 
become tumorigenic.  A prime example of such efforts is the characterization of the 
genetic alterations that occur in the progression from benign epithelial hyperplasia to 
invasive carcinoma in colon cancer.  However, tumors are not composed of an isolated 
mass of transformed epithelial cells, but of a composite of extracellular matrix, blood 
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vessels and immune cells, among other stromal components.  These components outside 
of the epithelial compartment are known as the tumor microenvironment.57 It is now 
widely accepted that communication and interactions between transformed epithelial 
cells and its microenvironment are essential for development, progression and therapeutic 
response of any neoplastic growth, and that components within this microenvironment 
can be exploited therapeutically.58  Immune cells are one of the most widely represented 
cells in the tumor microenvironment, and within this group, cells of the myeloid lineage, 
particularly monocyte/macrophages (tumor associated macrophages – TAMs), are of the 
most abundant.   
 
Monocytes and macrophages 
Macrophages are characterized by their remarkable plasticity.  Depending on the 
micro-environmental needs, their functions can range from immune activation and 
pathogen recognition and clearance to scavenging, immune suppression and wound 
healing.  This wide variety of, and sometimes opposing, functions underline the ability of 
macrophages to sense cues from the microenvironment and adapt to these so that 
appropriate immunological responses can be mounted.  In this way, macrophages 
function as switches of the immune system and can develop into different subsets to tailor 
and regulate immune responses.59   
The most widely accepted model of macrophage differentiation is the M1-M2 
polarization spectrum.  In one end, M1 macrophages are considered to be pro-
inflammatory monocytes that activate the immune system via inflammatory cytokine 
production and antigen presentation.  This subset of macrophages is activated by 
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microbial products such as lipopolysaccharide (LPS) and pro-inflammatory molecules 
such as IFNγ and they aid in the process of pathogen recognition and clearance.59 On the 
other end, M2 macrophages are activated by IL4 and IL13 and they function to keep the 
immune system in check by producing large amounts of anti-inflammatory molecules 
that regulate and terminate inflammatory reactions initiated by M1 polarized 
macrophages.  Furthermore, M2 polarized macrophages have scavenging and pro-
angiogenic properties that are important in the normal process of wound healing.60-61  At 
any given moment, macrophages exist somewhere in the middle of this spectrum with 
environmental signals tilting the pro- and anti-inflammatory balance to one side or the 
other.    
Although macrophages can potentially have anti-tumor effects, the bulk of the 
evidence available so far suggests that tumor associated macrophages (TAMs) enhance 
tumor survival and hamper response to therapy in a wide variety of solid tumors, 
including breast carcinoma, prostate carcinoma, bladder carcinoma and gliomas.62-67 In 
gliomas, monocyte/macrophages are one of the most widely represented cells within the 
tumor microenvironment.68  Studies aimed at understanding the characteristics of these 
cells within gliomas have shown that the bulk of these tumor-associated macrophages are 
M2-polarized, a profile consistent with a pro-tumorigenic phenotype.69 The mechanisms 
through which these cells can promote tumor progression are varied and include 
diminished anti-tumor activity, immune suppression and the production of cytokines and 
chemokines that induce glioma cell proliferation, angiogenesis and invasion.  
Furthermore, glioma cells are capabable of producing soluble mediators that perpetuate 
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this pro-tumorigenic phenotype in macrophages establishing this way a vicious cycle 
leading to enhanced malignancy.70 
 
Tie2 expressing monocytes 
As the name implies, Tie2 expressing monocytes (TEMs) are a subpopulation of 
circulating monocytes expressing the Tie2 receptor.  They were discovered in 2005 by De 
Palma et. al. as an effort to characterize the Tie2 expressing cell population within 
tumors.71 Through the use of a transgenic mouse model in which GFP expression was 
driven by transcriptional regulatory elements present within the Tie2 gene [TgN(Tie2-
GFP)], they identified a population of Tie2 expressing cells within the stromal 
compartment of N202 mammary tumors that co-express the monocytic marker CD11b, 
i.e Tie2 expressing monocytes. Co-injection experiments in which nude mice were 
implanted with N202 mammary carcinoma cells in conjunction with TEMs isolated from 
TgN(Tie2-GFP) mice, demonstrated that TEMs have remarkable pro-angiogenic 
properties, with tumors co-injected with TEMs having a 4-fold higher average vascular 
area than controls.  As a continuation of this work, in 2007 Venneri et al. described the 
presence of TEMs in peripheral blood of healthy donors, as well as in human tumor 
samples, establishing a link between the findings in the mouse mammary tumor model 
and human disease.72  Tie2 expressing monocytes have also been studied in the context of 
hepatocellular carcinoma.  Matsubara et al. showed that TEMs increase in patients 
suffering from HCC and that their numbers correlate with response to therapy, i.e. 
surgery, as well as tumor recurrence.73 Given these data, the authors highlight the 
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potential of using TEMs as biomarker for HCC.  Finally, their selective recruitment to 
tumors has been exploited as a tool for drug delivery.74 
Due to their relatively recent discovery, reports on TEMs and their biological 
properties are still limited.  The bulk of the research performed so far has been directed to 
further elucidate their role in tumor angiogenesis and progression.  In 2009, Pucci et al. 
analyzed the gene signature of TEMs in comparison to TAMs, endothelial cells and other 
myeloid derived cells, such as neutrophils.75  Their work further confirmed that TEMs are 
part of the myeloid lineage, since they posses higher expression of myeloid genes such as 
csf1, Fc receptors and cd14, while having negligible amounts of endothelial derived 
genes.  Their expression profile is also consistent with their pro-angiogenic role, having 
higher expression of mRNAs classically associated with angiogenesis, such as vegfa, 
vegfb, and pdgf.  Furthermore, expression of M2 polarization markers such as arginase 
and mannose receptor placed TEMs in this end of the monocyte/macrophage polarization 
spectra, further supporting their pro-tumorigenic properties.69, 75 The role of the Tie2 
receptor in this monocyte subpopulation is still unclear.  However, the Tie2 ligand Ang2, 
has been shown to promote their pro-angiogenic and pro-tumorigenic properties.  In their 
work published in 2009, Coffelt et al. provided evidence that Ang2 can recruit TEMs to 
tumors and enhance their pro-angiogenic properties.76 In their follow up work, they 
extended the role of TEMs to that of an immunomodulatory cell capable of inducing an 
immune suppressed microenvironment through the expression of IL10.  Interestingly, 
Ang2 was capable of further enhancing their expression of this cytokine, which then led 
to suppression of T cell proliferation, increase in the CD4+/CD8+ T cell ratio and 
expansion of Tregs.77 Therefore, although literature on TEMs is still limited, the bulk of 
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the evidence heavily supports the notion that this cell population support tumor 
progression and their presence could be associated with worse patient prognosis 
 
Glioblastoma multiforme is one of the deadliest malignancies known to man.  
Extensive research efforts have only led to modest advances in therapy and patient 
outcomes.  The purpose of this investigation is to better understand the events leading to 
recurrence following anti-VEGF therapy (i.e. bevacizumab) in GBM with the ultimate 
goal of identifying new therapeutic targets for combined treatment.  Based on the 
available evidence, we hypothesize that the Ang-Tie2 pathway plays a key role in the 
recurrence of GBM after anti-angiogenesis treatment.  A corollary of this hypothesis 
being that targeting this pathway in combination with anti-VEGF therapy could lead to 
improved outcomes in GBM. 
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Chapter II: Materials and Methods 
 
Cell Culture. U87 malignant glioma and THP-1 monocytic leukemia cell lines were 
obtained from the American Type Culture Collection. GSC20 glioma stem cells were 
established from a human glioblastoma surgical specimen at MD Anderson Cancer 
Center (Houston, TX).  GL261 mouse glioma cells were obtained through the NCI-
Frederick Cancer Research Tumor Repository (Frederick, MD).  GL261.GFP and 
GL261.sTie2 established cell lines were a kind gift from Luc Vallières (Quèbec, CA), 
Ph.D. U87 MG cells were cultured in Minimum Essential Medium Eagle (MEM) with 
10% FBS and 1% essential amino acids under the same conditions.  THP-1 monocytic 
leukemia cell line was cultured in RPMI1640 media supplemented with 2mM L-
glutamine and 10% FBS.  GSC20 glioma stem cells were cultured using Dulbecco’s 
Modified Eagle Medium/F12 supplemented with 1X B27 and 20ng/mL bFGF and 
20ng/ml EGF. GL261, GL261.GFP and GL261.sTie2 cell lines were cultured in 
Dulbecco’s Modified Eagle Medium/F12 supplemented with 10% FBS.  All media was 
supplemented with 100µg/ml penicillin and 100µg/ml streptomycin. 
 
Immunohistochemistry. Five µm sections were deparaffinized in three washes of xylene 
for 5 minutes each, followed by rehydration in serial dilutions of ethanol as follows: 
100% ethanol twice for 5 minutes, 95% ethanol twice for 5 minutes and 70% ethanol 
once for 5 minutes.  Following a brief wash in PBS, endogenous peroxidase activity was 
quenched using 3% H2O2 in 100% methanol for 10 minutes at room temperature.  Heat- 
induced antigen retrieval was performed in a pre-warmed solution of 10mM citrate 
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buffer, pH6 for 10 minutes in a pressure cooker.  Slides were allowed to cool down at 
room temperature for 30 minutes before washing and blocking using a 5% BSA in PBS 
solution.  Primary antibodies were diluted using IHC Tek diluent pH 7.4 (IHC World, 
Cat. # IW1000) and placed at 4°C overnight.  Biotin-conjugated secondary antibodies 
(Vector Labs) were diluted 1:400 in IHC Tek diluent pH 7.4 and applied to tissue 
sections for 1 hour at room temperature.  This was followed by incubation with ABC 
system (Vector labs, Cat. # PK4000) for one hour at room temperature.  3, 3’ 
diaminobenzidine (Sigma, Cat. # D4418) was used for signal detection.  Nuclei 
counterstain was done using hematoxilin, after which slides were dehydrated in 100% 
ethanol.  Following a brief wash in xylene slides were mounted using CytoSeal (Thermo 
Scientific, Cat. # 23-244257).  Images were taken using a brightfield, Zeiss Axioskop 40 
microscope at the designated magnification. 
 
Immunofluorescence. Five µm sections were deparaffinized in three washes of xylene 
for 5 minutes each, followed by rehydration in serial dilutions of ethanol as follows: 
100% ethanol twice for 5 minutes, 95% ethanol twice for 5 minutes and 70% ethanol 
once for 5 minutes.  Blocking was done with a 5% BSA in PBS solution followed by 
primary antibody diluted in IHC Tek diluent at 4°C overnight.  Biotin-conjugated 
secondary antibodies were diluted 1:500 in IHC Tek diluent pH7.4 and placed on tissue 
sections for one hour at room temperature.  Dylight-conjugated streptavidin was used for 
signal detection.  When required, signal was amplified by an additional step of biotin-
conjugated anti-streptavidin antibody (Vector Labs, Cat. # BA0500, 1:1000) for 30 
minutes at room temperature followed by an additional step of Dylight-conjugated 
 20 
streptavidin (Vector Labs, Cat. # SA-5488-1 and SA-5549-1, 1:1000) for 30 minutes at 
room temperature.  DAPI was applied for 15 minutes at room temperature for nuclear 
counterstaining. Slides were then mounted using Dako Fluorescence Mounting Medium 
(DAKO, Cat. # S3023). Images were taken in a fluorescent Zeiss Axiovert 200M 
microscope at 20x magnification.  For quantification purposes, at least eight pictures of 
random fields were taken and manually quantified per slide. 
Primary antibodies used for immunohistochemistry and immunofluorescence are 
Ang2 (IHC World, ready-to-use), Ang1 (R&D, 1:100), VEGF (Santa Cruz, 1:500), Iba1 
(Millipore, 1:1000), CD31 (R&D, 1:100), SMA (Dako, 1:100), hNuMA (abcam, 1:500),.  
Secondary antibodies used are biotinylated anti-rabbit (Vector Labs), biotinylated anti-
mouse (Vector Labs), biotinylated anti-goat (Vector Labs).  Dylight-594 and Dylight-488 
conjugated streptavidin (Vector Labs) was used for immunofluorescence detection. 
 
M2 polarization and induction of Tie2 expression in THP-1 monocytic leukemia cell 
line. THP-1 cells were placed in serum free media in the presence of 20ng/ml IL4 (R&D, 
Cat. #204-IL-010) and 20ng/ml IL13 (R&D, Cat. #213-ILB-005) and placed in hypoxic 
conditions (1% O2, 5% CO2 and 94% N2) for 48-72 hours.  Tie2 expression was measured 
via flow cytometric analysis following polarizing conditions. 
 
Flow cytometric analysis. Cells of interest were harvested and washed three times with a 
solution of PBS containing 0.5% BSA.  Incubation with primary antibodies was 
performed at 4°C for 30 minutes in the dark, after which cells were washed twice with 
PBS.  Cells were resuspended in 500ul-2mL of PBS depending on total number of cells.  
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Flow cytometry was done using a FacsCalibur flow cytometer from Beckton Dickinson 
machine and expression was analyzed using CellQuest software.  In experiments 
requiring sorting, expression was analyzed and sorting was performed using a 
FACSAriaII cell sorter from Beckton Dickinson. 
Primary antibodies used were phycoerythrin-conjugated mouse anti-human Tie2 (1:50, 
R&D, Cat. #FAB3131P), fluorescein-isothyocyanate conjugated mouse anti-human 
CD11b (1:50, Abcam, Cat. # ab25827-100), allophycocyanin conjugated mouse anti-
human CD14 (1:50, R&D, Cat. #FAB3832A). 
 
Isolation of monocytes from peripheral blood of healthy donors.  Peripheral blood 
mononuclear cells (PBMCs) were prepared from healthy donor blood (Gulf Coast 
Regional Blood Center, Houston, TX) by centrifugation on a Ficoll-Paque Plus (GE 
Healthcare, Cat. # 17-1440-02) density gradient at 950g for 20 minutes, with deceleration 
set at zero.  PBMCs were incubated in the presence of 20µl per 1x107 cells CD14 
MicroBeads (Miltenyi Biotech, Cat. # 120-000-305) for 20 minutes at 4°C after which 
cells were run through a magnetic column to isolate CD14 positive monocytes.  
Monocyte-enriched population was then double stained with anti-human CD14-APC 
(R&D Systems, Cat. # FAB3832A) and anti-human Tie2-PE (R&D Systems, Cat. # 
FAB3131P).  Stained cell suspension was then subjected to flow cytometric analysis and 
cell sorting (FACSAria, Becton Dickinson) to obtain Tie2-negative (CD14+/Tie2-) and 
Tie2-expressing monocytes (CD14+/Tie2+).  
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Migration assays. For migration assays, THP-1 cells were placed in either normoxia or 
hypoxia conditions in the presence or absence of 20ng/ml IL-4 and 20ng/ml IL-13 for 48 
hours. In some experiments, cells were sorted according to Tie2 expression prior to 
migration assay.  For this purpose, cells were stained using phycoerythrin-conjugated 
anti-Tie2 antibody (R&D, Cat. #FAB3131P) and subjected to flow cytometric analysis 
and cell sorting using Becton Dickinson FACS Aria II. 
24-well plates were used for migration assay with a transwell containing a 5µm 
pore polycarbonate membrane (Corning, Cat. # 3422).  Depending on the experiment, 
1x105 treated or sorted THP-1 cells, were placed in a transwell, which was then placed 
over a well containing 500µl of either 400ng/ml Ang2 (R&D, Cat. #623-AN-025) in 
serum-free media or the equivalent amount of BSA. Cells were allowed to migrate for 24 
hours, after which total number of migrated cells in the lower chamber was counted with 
a hemocytometer using Trypan Blue.  Results shown are the mean from three separate 
migrations. 
 
Invasion assays. For invasion assays, THP-1 cells were placed in normoxia or hypoxia 
conditions in the presence or absence of 20ng/ml IL-4 and 20ng/ml IL-13 for 48 hours. In 
some experiments, cells were stained using phycoerythrin conjugated anti-Tie2 antibody 
(R&D, 1:50) and subjected to flowcytometric analysis and cell sorting using Becton 
Dickinson FACS Aria II.  Following sorting or polarizing conditions, cells were cultured 
in RPMI media containing 1% fetal bovine serum for 24 hours.  Conditioned media from 
Tie2 negative and Tie2 positive cells were then collected and used for invasion assay. 
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24-well plates were used for invasion assay with a transwell containing an 8µm 
pore polycarbonate membrane (Corning, Cat. #3422).  Membrane was coated with 
0.3mg/ml LDEV free, growth factor reduced matrigel matrix (BD Biosciences, Cat 
#356230).  Matrigel was allowed to solidify at room temperature for 2 hours prior to the 
experiment.  Depending on the experiment, 1x105 U87 glioma cells or GSC20 glioma 
stem cells were seeded on the transwell, which was then placed over a well containing 
500µl of conditioned media from either Tie2-negative or Tie2-positive monocytes. Cells 
were allowed to invade for 24 hours, after which cells in the transwell were fixed and 
stained using a solution of 0.1% crystal violet in 20% methanol at room temperature for 
20 minutes.  Non-invading cells within the upper portion of the transwell were removed 
using a cotton swab and invading cells attached to the bottom side of the transwell were 
quantified. 
 
Gelatinase activity assay. Tie2 negative and Tie2 positive monocytes were obtained from 
donor blood as described above.  After sorting, cells were cultured in serum free media 
for 24 hours after which conditioned media was used to detect gelatinase activity using 
EnzCheck® Gelatinase/Collagenase Assay Kit (Life Technologies, Cat. #E12055) as per 
manufacturer’s instructions.  Briefly, conditioned media was incubated in the presence of 
fluorescein-conjugated DQ-gelatin from pig skin at room temperature overnight in the 
dark.  Fluorescence was measured at 495nm. 
 
Enzyme-linked immunosorbent assay. Tie2-positive and Tie2-negative monocytes were 
isolated from peripheral blood as described above.  After sorting, cells were cultured in 
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serum free media for 24 hours after which conditioned media was collected.  MMP2 and 
MMP9 were detected using Quantikine ELISA Kit (R&D, Cat#MMP200 and DMP900) 
as per manufacturer’s instructions.  Briefly, conditioned media was diluted with Assay 
Diluent provided and added to each well.  After a 2 hour incubation at room temperature, 
wells were washed and conjugated antibody against the protein of interest was added to 
each well.  After a 2 hour incubation period, wells were washed and a mixture of Color 
Reagent A and Color Reagent B was added to the wells for at least 30 minutes.  The 
reaction was stopped using a sulfuric acid based solution and absorbance was read at 
450nm. 
 
BrdU incorportation assay. Cells were plated in a 96-well plate and allowed to attach 
overnight.  BrdU incporation assay was performed using BrdU Cell Proliferation Assay 
Kit (Cell Signaling, Cat #6813) as per manufacturer’s instructions.  Briefly, cells were 
incubated at 37°C overnight in the presence of labeling agent.  Media was aspirated and 
cells were exposed to Fixing/Denaturing solution followed by incubation in detection 
antibody solution at room temperature.  Cells were then incubated in HRP-conjugated 
secondary antibody followed by TMB substrate.  Reaction was stopped after 30 minutes 
using the provided Stop solution and absorbance was measured at 450nm.  
 
In vivo experiments. All animal studies were performed in the Department of Veterinary 
Medicine at The University of Texas MD Anderson Cancer Center (Houston, TX) in 
accordance with institutional and ethical guidelines for experimental animal care and 
approved by the MD Anderson IACUC.  
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U87MG cells (5x105) were implanted intra-cranially in the caudate nucleus of 
athymic mice as described before.  Briefly, a 2.6-mm guide screw with a 0.5-mm 
diameter central hole is implanted into a drill hole made 2.5 mm lateral and 1 mm 
anterior to the bregma. It is capped with a stylet between treatments. Tumor cells were 
injected using a 26-gauge needle of a Hamilton syringe with a cuff to determine the depth 
of injection. VEGF Trap was administered subcutaneously at 25mg/kg, twice a week 
starting 10 days after implantation and continued for either 3 weeks or 6 weeks.  
Bevacizumab treatment was administered intraperitoneally at 10mg/kg starting on day 5 
post-implantation and continued for 6 weeks.  Temozolomide treatment was administered 
intraperitoneally at 7.5 mg/kg/day on days 4-8 and 11-22 post-implantation.  Mice were 
sacrificed when signs of high tumor burden were apparent.  Brains were extracted, 
formalin fixed and paraffin embedded.  Five µm sections were cut and mounted on slides 
for histological and protein expression analysis. 
GL261, GL261.Ctrl or GL261.sTie2 mouse glioma cells (2x105) were implanted 
intracranially into the caudate nucleus of C57/BL6 mice as described above.  DC101 
treatment was administered intraperitoneally at 800µg/dose three times a week for a total 
of 4 weeks.  Mice were sacrificed when signs of high tumor burden were apparent.  
Brains were extracted, formalin fixed and paraffin embedded. Five µm sections were cut 
and mounted on slides for histological and protein expression analysis. 
 
Statistical Analysis.  The two-tailed Student t-test was used to determine the statistical 
significance in in vitro experiments. Log-rank test was used to determine statistical 
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significance of in vivo survival. Only p values less than 0.05 were accepted as statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
Chapter III: Tie2 expressing monocytes are recruited to the tumor following anti-
VEGF therapy 
 
Rationale and expectations 
In the process of angiogenesis, there is a tight interplay between the VEGF pathway and 
the Ang-Tie2 pathway.  This led us to hypothesize that in the context of anti-angiogenesis 
therapy, the Ang-Tie2 pathway could be upregulated as a means to escape VEGF 
blockade.  To test this, we initially evaluated the presence of Tie2 within tumors 
following anti-VEGF therapy.  We hypothesized that there would be an increase in Tie2 
following anti-angiogenesis treatment. 
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Results 
 
Tie2-expressing cells accumulate in the periphery of the tumor after anti-VEGF 
therapy. Tumor sections from glioma-bearing mice treated with either control hFc or 
aflibercept were obtained and immunostaining for Tie2 was performed (Figure 1).  We 
tested two different VEGF-Trap/aflibercept schedules: a short 3-week schedule that did 
not lead to an enhanced invasive pattern and a prolonged 6-week schedule that led to the 
appearance of invasive nodules.  As can be observed, there is a marked increase in the 
number of Tie2-expressing cells in tumors treated with anti-VEGF therapy, particularly 
in the periphery of the tumor and surrounding areas of invasion.  Quantification of 
positive cells shows this increase in Tie2-positive cells to be significant and 
circumscribed to the periphery of the tumor.  Interestingly, this significant increase in 
Tie2 positive cells is only observed after prolonged (6-week) anti-VEGF therapy, 
whereas 3-week treatment does not lead to an increase in these cells.   
The morphological features of the Tie2 positive cells suggested they were not U87 
glioma cells.  They were characterized by small, rounded and normal appearing nuclei 
with scant cytoplasm, which suggests they could be circulating immune cells infiltrating 
the tumor or resident cells, such as microglia, proliferating from within the tumor. 
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Tie2 expressing monocytes are recruited to the tumor following anti-VEGF therapy.  
Monocytes/macrophages are one of the most abundant cells within the tumor 
microenvironment in gliomas.68 Given the morphological features, we hypothesized that 
these Tie2-expressing cells were in fact Tie2 expressing monocytes that are recruited to 
the tumor following anti-VEGF therapy. To test our hypothesis, we obtained tissue 
sections from glioma-bearing mice treated with VEGF-Trap/aflibercept for 3 or 6 weeks, 
bevacizumab or temozolomide.  Double staining for Iba1, a monocyte/microglia marker, 
and Tie2 was performed and double positive cells were quantified.  Our results confirmed 
our hypothesis showing a marked and significant increase in the number of double 
positive cells following anti-VEGF therapy with VEGF-Trap/aflibercept or bevacizumab.  
TEMs were mainly localized around the tumor periphery and areas of invasion.  Again, 
this increase TEMs was only observed after a prolonged schedule of VEGF-
Trap/aflibercept when invasion occurs.  Furthermore, treatment with temozolomide did 
not lead to a similar outcome, providing evidence that TEMs are being selectively 
recruited as a response to anti-angiogenic treatment. 
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Conclusions 
 
Tie2-expressing cells, and Tie2-expressing monocytes in particular, are selectively 
recruited to the tumor following prolonged anti-VEGF therapy.  This recruitment occurs 
only after a prolonged schedule of anti-VEGF therapy, when invasion appears.  
Furthermore, they accumulate around the peripheral areas of the tumor, and particularly 
around invasive nodules.  This result suggests a role for this cell population in the 
invasive phenotype observed after anti-angiogenic therapy. 
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Chapter IV: Increased Ang2 expression is associated with the development of invasion 
following anti-VEGF therapy 
 
Rationale and expectations 
We have shown an accumulation of Tie2-expressing cells, and Tie2-expressing 
monocytes in particular, around the periphery of the tumor following anti-VEGF therapy.  
We wanted to further elucidate the status of the Ang-Tie2 pathway following anti-VEGF 
therapy, hypothesizing that there was an upregulation of angiopoietin expression leading 
to recruitment of Tie2-expressing monocytes to the tumor and potentially modulating 
their behavior to aid in the invasive process.  At the moment of this study, there were 
various reports correlating Ang2 expression with overexpression of MMP2 and invasion 
in glioma.78-79 Furthermore, Ang2 has been shown to be expressed in human GBM 
surgical samples to a greater extent than in lower grade astrocytomas, particularly in 
peripheral areas nad invasive cells.78 Therefore, we expected to find an upregulation of 
Ang2 following anti-VEGF therapy and that this had an important role in TEM 
recruitment as well as the invasive recurrence of gliomas after treatment. 
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Results 
 
Ang2 expression is upregulated after prolonged treatment with VEGF-
Trap/aflibercept. Using tissue sections from glioma-bearing mice treated with either 
control hFc or VEGF-Trap/aflibercept for 3 or 6 weeks, we performed immunostaining 
for Ang1 and Ang2 (Figure 3).  Ang1 expression, as assessed by immunohistochemical 
staining, is below detection levels regardless of treatment status.  On the other hand, 
Ang2 expression dramatically increases following anti-VEGF therapy.  Interestingly, the 
increased expression is mainly circumscribed to the periphery of the tumor and invasive 
nodules, following the same pattern observed for TEMs.  We proceeded to perform 
immunofluorescence analysis for quantification purposes (Figure 4).  Results obtained 
show a significant increase in Ang2 positive cells following anti-VEGF therapy when 
compared to control treated tumors or tumors treated for 3 weeks, when invasion does not 
occur.   
Since VEGF has been associated with invasion in gliomas, we were interested in 
evaluating the effect of inhibiting VEGF in the expression of this ligand within the tumor 
(Figure 3).  Interestingly, we saw an upregulation of VEGF after VEGF/Trap aflibercept.  
However, we begin to see this upregulation after only 3 weeks of treatment when 
invasion does not occur.  This result suggests that increased VEGF expression is not 
sufficient to cause the invasive phenotype we observe after prolonged treatment. 
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Ang2 upregulation is a common phenomena to all VEGF targeted approaches. 
VEGF-Trap/aflibercept is a chimeric antibody composed of the VEGF binding domain of 
the VEGFR1 and VEGFR2 attached to the constant portion (Fc) of an IgG for 
solubilization.80 Therefore, it works a soluble ligand trap. It is currently in clinical trials 
for the treatment of recurrent GBM at MD Anderson Cancer Center.  Bevacizumab, on 
the other hand, is an anti-VEGF antibody that is currently FDA approved for the 
treatment of recurrent GBM.  To determine if bevacizumab treatment led to similar 
increases in Ang2 as VEGF-Trap/aflibercept, we performed immunostaining for Ang2 in 
tissue sections from glioma-bearing mice treated with bevacizumab or control hFc 
(Figure 5).  Our results show a dramatic increase in Ang2 expression in bevacizumab 
treated tumors in a similar pattern as that observed for aflibercept.  These data support 
that upregulation of Ang2 is a global phenomenon for VEGF targeted therapeutic 
approaches regardless of the means used to achieve inhibition. 
We then obtained fresh tissue protein lysate from tumors treated with either control 
treatment or bevacizumab treatment and performed ELISA to determine Ang2 
concentration within the tumor and normal brain from the contralateral hemisphere 
(Figure 6).  Our data show an increase in Ang2 expression in tumors treated with 
bevacizumab when compared to control treated tumors.  This change was not found to be 
statistically significant, possibly due to the inherent variability of in vivo models.  
Interestingly, Ang2 was barely detectable in normal brain tissue regardless of treatment.   
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Temozolomide treatment does not lead to increased Ang2 expression. Temozolomide 
(TMZ) is the currently approved chemotherapeutic agent for patients with newly 
diagnosed glioblastoma.  We wanted to see if upregulation of Ang2 expression was 
specific for anti-VEGF approaches or if other therapeutic regimes could also lead to 
similar effects.  To evaluate this, we performed immunohistochemical staining for Ang2 
in tissue sections from glioma-bearing mice treated with either control PBS or TMZ 
(Figure 7).  Our results show that following TMZ treatment, Ang2 remains localized 
mainly in vascular structures and it is not increased as observed for anti-VEGF therapy.  
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Characterization of Ang2-expressing cells following anti-VEGF therapy. Given the 
varied morphological features of the cells expressing Ang2 after anti-VEGF therapy, we 
proceeded to characterize the major contributing cell to the Ang2 pool.  For this purpose, 
we performed double immunofluorescence for Ang2 in combination with α-SMA as a 
marker for pericytes, CD31 as a marker of endothelial cells, Iba1 as a marker of 
monocytes or NuMA as a marker of cells from human origin to distinguish glioma cells.  
As expected, our results show that pericytes are not a significant source of Ang2, 
regardless of treatment.  As can be seen in the inset the two dyes do not colocalize 
(Figure 8).  On the other hand, the vast majority of endothelial cells within the tumor bed 
express Ang2 as can be shown by the colocalization of the two dyes in the representative 
picture (Figure 9).  However, the relative contribution of endothelial cells to Ang2 does 
not change significantly with treatment as appreciated in the quantification (lower panel, 
Figure 9).  Interestingly, monocytes are a significant source of Ang2 (Figure 10), but 
upon quantification, their relative contribution decreases with treatment.  Given the 
morphological features of the Ang2 expressing cells, we hypothesized that glioma cells 
upregulate their expression of Ang2 becoming an important source following anti-
angiogenic therapy.  Since it is very difficult to obtain a cell marker that homogeneously 
stains all glioma cells, we took advantage of the fact that we are using a human glioma 
cell line on a mouse model.  We obtained an antibody that detects only the human form 
of the nuclear mitotic apparatus protein (NuMA) and used it to differentiate glioma cells 
from all other cells in the tumor micorenvironment.  Using this antibody, we performed 
double immunofluorescence staining with Ang2 to determine the contribution of glioma 
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cells to the Ang2 pool (Figure 11).  Taken together, our results show that only within the 
glioma compartment is there a significant increase in the relative contribution of Ang2.   
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Conclusions 
 
Ang2, a Tie2 ligand, is upregulated following anti-VEGF therapy following the same 
spatial pattern as that observed for TEMs.  This increase in Ang2 is specific for anti-
VEGF targeted approaches, since treatment with temozolomide did not lead to similar 
changes.  Furthermore, characterization of the cells expressing Ang2 showed that the 
glioma compartment significantly upregulates expression in response to anti-VEGF 
therapy.  These data suggest that Ang2 is an important mediator of glioma-acquired 
resistance to anti-VEGF therapy and the invasive phenotype observed upon recurrence.   
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Chapter V: Ang2 leads to TEM recruitment after anti-VEGF therapy 
 
Rationale and expectations 
Ang2 is one of the most studied ligands of Tie2 and it is known to cooperate with VEGF 
in the process of angiogenesis.  Given our data on TEM recruitment and Ang2 
overexpression after anti-VEGF therapy, we hypothesized that Ang2 is responsible for 
the recruitment of TEMs to the tumor following anti-VEGF therapy.  We expect Tie2 
expressing monocytes to have an enhanced migratory response in the presence of Ang2 
than their Tie2 negative counterparts in vitro and in vivo. 
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Results 
 
Ang2 induces migration in polarized THP-1 cells, and in particular Tie2 expressing 
THP-1 cells.  Studying cells of monocytic origin can be very difficult due to their short 
duration in culture once isolated from buffy coats.  Additionally, TEMs represent 10% or 
less of the monocytic population of a normal patient, adding to the difficulty of studying 
them.  Given these problems, we designed a method to generate TEMs using the THP-1 
monocytic leukemia cell line.  As described in the materials and methods section, THP-1 
cells were M2 polarized and induced to express Tie2 by exposure to hypoxia for 48 hours 
in the presence of M2 polarizing cytokines, IL4 and IL13.  As controls, cells exposed to 
normoxia, normoxia with IL4 and IL13 and hypoxia alone were also evaluated for the 
expression of Tie2 (Figure 12).  Following 48-72 hours in these conditions, cells were 
either used directly and compared to cells placed in normoxia, or sorted for Tie2 
expression before migration experiments were done.  
After verifying the increase in Tie2 expression following polarizing conditions (Figure 
12), migration towards Ang2 of cells exposed to hypoxia with interleukins was tested and 
compared to cells placed in normoxia (Figure 13).  Our results show a significant 
increase in the number of migrating cells in the cells exposed to hypoxia with IL4 and 
IL13 compared to cells placed in normoxia.  To determine whether this increased 
migratory response is due to the presence of Tie2 expressing monocytes, we proceeded to 
sort THP-1 cells after Tie2 induction and polarizing conditions.  Migration of Tie2 
negative and Tie2 positive cells towards Ang2 was then evaluated (Figure 14).  Our 
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results show a significantly higher number of migrating cells in the Tie2 positive THP-1 
group than their Tie2 negative counterparts.   
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Ang2 leads to TEM recruitment in vivo. To evaluate whether our in vitro findings had 
any relevance in the in vivo setting, we proceeded to determine if high Ang2 expression 
within the tumor led to increased number of TEMs.  For this purpose, tissue sections 
from glioma-bearing mice infected with an adenovirus overexpressing Ang2 (AdAng2) 
were obtained.  To detect and quantify TEMs, double immunofluorescence for Tie2 and 
Iba1 was performed (Figure 15).  Our results show a dramatic and highly significant 
increased number of TEMs in tumors treated with AdAng2 when compared to tumors 
treated with AdCMV (empty adenovirus).  This confirms that Ang2 is chemoattractant to 
TEMs both in vitro and in vivo.  
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Conclusions 
 
Ang2 stimulates migration of Tie2 expressing monocytes, both in vitro and in vivo.  
These data provide evidence that Ang2 is capable of recruiting Tie2 expressing 
monocytes following anti-VEGF therapy. It is worth noting that since our experiments 
were performed, another group published similar results in an in vitro setting, which 
further validates our data.72 
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Chapter VI: Tie2 expressing monocytes promote an environment conducive for 
invasion 
 
Rationale and expectations 
Tie2 expressing monocytes are a recently discovered subset of circulating monocytes that 
express the Tie2 receptor.71  They have been shown to be highly pro-angiogenic and 
Ang2 has been shown to further enhance their pro-angiogenic properties.72  There is a 
tight interplay between the process of angiogenesis and the process of invasion, with 
extensive overlapping in terms of molecules required and associated with each.  For 
example, MMPs are required to partially degrade the ECM to allow for endothelial 
migration during the process of angiogenesis.  But, they are also known to promote tumor 
invasion and metastasis.  Based on the distribution and temporal appearance of TEMs, we 
hypothesized they play an important role in the invasive phenotype after anti-VEGF 
therapy.  We hypothesized a higher production of pro-invasive molecules, such as 
MMPs, in Tie2 positive monocytes when compared with their Tie2 negative counterparts.  
Furthermore, we expect Ang2 to further enhance the secretion of said molecules. 
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Results 
 
TEMs secrete higher amounts of pro-invasive molecules than their Tie2 negative 
counterparts. So far we have shown that anti-VEGF therapy leads to an increase in 
Ang2 expression which then leads to recruitment of TEMs.  We hypothesized that this 
increased representation of TEMs is generating an environment conducive for invasion 
through the secretion of pro-invasive molecules that facilitate the process.  To test this 
hypothesis, we obtained TEMs from peripheral blood of healthy donors as described in 
the material and methods section.  Figure 16 shows a representative sorting experiment. 
Once Tie2 positive and Tie2 negative monocytes were obtained, we cultured them in 
serum free media for 24 hours, time after which media was collected and the secretion of 
MMP2 and MMP9 was assessed via ELISA (Figure 17). Our results show a highly 
significant increased level of expression of both of these molecules by TEMs, when 
compared to their Tie2 negative counterparts, supporting the idea that the presence of 
TEMs is at least partially responsible for the pattern of recurrence following anti-VEGF 
therapy. 
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Tie2 expressing cells, potentially TEMs, express MMP9 in vivo. Given the selective 
recruitment of TEMs to the periphery of the tumor following anti-VEGF therapy, and 
their high expression of MMP9 we wanted to determine whether MMP9 expression was 
upregulated within the tumor following anti-VEGF therapy.  To evaluate this we 
performed MMP9 immunohistochemistry in tissue sections from glioma-bearing mice 
treated with control hFc or VEGF-Trap/aflibercept for 6 weeks.  Our results show a 
significant increase in the expression of MMP9 following anti-VEGF treatment (Figure 
18). 
To determine if Tie2 expressing monocytes could be a source of MMP9 in vivo we 
performed double immunostaining to detect Tie2 and MMP9 in tissue sections from 
glioma-bearing mice treated with bevacizumab (Figure 19).  We evaluated dye 
colocalization and were able to detect double positive cells around the periphery of 
tumors treated with bevacizumab.  Analysis through confocal microscopy shows 
colocalization of the two colors within one cell (lower panel, Figure 19).  Morphological 
features of these cells support the idea of them being Tie2-expressing monocytes.  
However, triple staining adding Iba1 as a monocyte/microglia marker would be helpful to 
determine the exact contribution from this cell population to the MMP9 pool.  
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Conditioned media from TEMs induces glioma cell invasion in vitro. Given the 
significantly higher expression of MMPs observed for TEMs, we hypothesized that 
glioma cells would exhibit higher invasion in the presence of conditioned media from 
these cells.  To test this possibility we initially polarized THP-1 cells in hypoxia with IL4 
and IL13 treatment for 48 hours. After 48 hours, Tie2 expression was confirmed through 
flow cytometric analysis (Figure 12) and conditioned media was harvested and used for 
invasion assays with U87 glioma cells (Figure 20).  We observed a significantly higher 
number of invading U87 glioma cells when conditioned media from THP-1 cells grown 
under hypoxia conditions was used.  This increased invasion was further enhanced when 
conditioned media from cells also exposed to IL4 and IL13 M2 polarizing cytokines was 
used.  This further enhancement was also shown to be significant. 
To determine if this increased invasion was due to the presence of TEMs, we exposed 
THP-1 cells to hypoxia with IL4 and IL13 for 48 hours after which cells were sorted 
according to Tie2 expression.  After sorting, cells were cultured in serum free media for 
24 hours after which conditioned media was harvested and used for invasion assays 
(Figure 21).  Our results show a significant increase in the number of invading U87 
glioma cells and invading GSC20 glioma stem cells in the presence of conditioned media 
from TEMs when compared to those in the presence of conditioned media from Tie2 
negative monocytes. 
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Ang2 further enhances the secretion of pro-invasive molecules by TEMs. We have 
already shown that Ang2 is at least partially responsible for the increased representation 
of TEMs within the tumor after anti-VEGF therapy.  We hypothesized that Ang2 is 
capable of further enhancing their pro-invasive capabilities. To test this, we obtained Tie2 
positive and Tie2 negative monocytes from peripheral blood of healthy donors as 
described in the material and methods section.  Once cells were obtained, both Tie2+ and 
Tie2- monocytes were cultured in serum free media in the presence or absence of Ang2 
for 24 hours.  At 24 hours, media was collected and gelatinase activity was measured 
using the EnzChek Gelatinase/Collagenase Assay (Figure 22).  This kit uses a fluorescein 
conjugated DQ-gelatin that is so highly labeled that fluorescence is quenched.  Gelatinase 
activity digests the substrate and produces highly fluorescent fragments.  Fluorescence 
levels correlate with gelatinase activity.  Results obtained show that media obtained from 
TEMs has higher gelatinase activity as shown by the significantly higher fluorescence in 
the absence of Ang2 when compared to their Tie2 negative counterparts.  Furthermore, 
our data confirms our hypothesis that Ang2 further enhances this secretion as the 
gelatinase activity significantly increased in the presence of Ang2.  Interestingly, Ang2 
only enhanced the pro-invasive activity in the Tie2 positive population which suggests its 
effect is mediated by the Tie2 receptor. 
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Conclusions 
 
Through the expression of pro-invasive molecules, such as MMP2 and MMP9, TEMs are 
capable of modifying the tumor microenvironment making it one conducive for invasion.  
There is an increase in the expression of MMP9 following anti-VEGF therapy and our 
data suggests that TEMs are at least partially responsible for this phenomena. 
Highlighting the significance of these findings, we were able to show that glioma cells 
display enhanced invasive capabilities in the presence of conditioned media from TEMs.  
These data demonstrates the importance of TEMs and the Ang-Tie2 pathway in the 
invasive recurrence of GBM after anti-VEGF therapy. 
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Chapter VII:  Targeting the Ang-Tie2 pathway in combination with anti-VEGF 
therapy leads to improved outcomes in syngeneic mouse glioma model. 
 
Rationale and expectations 
GBM is a highly aggressive cancer characterized by infiltration into the normal brain.  
Recently, bevacizumab was added to the battery of treatments offered to patients with 
recurrent GBM and although it has important anti-tumor effects, patients treated with 
bevacizumab invariably present with recurrent disease.56  Upon recurrence, these tumors 
acquire a highly malignant behavior characterized by enhanced invasion into adjacent 
normal brain which renders surgical excision ineffective.  Throughout this work we have 
provided evidence for the involvement of Ang-Tie2 pathway in the pattern of recurrence 
of gliomas following anti-VEGF therapy.  We hypothesized that by targeting the Ang-
Tie2 pathway in combination with anti-VEGF therapy we will observe improved 
outcomes in GBM. We expect to obtain improved survival outcomes as well as a 
decrease in the invasive phenotype seen with anti-VEGF monotherapy. 
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Results 
 
Targeting VEGFR also leads to an invasive phenotype in a mouse glioma model. To 
target the Ang-Tie2 pathway we obtained a GL261 mouse glioma cell line 
overexpressing a soluble form of the Tie2 receptor.  Upon release of sTie2, it will bind all 
the angiopoietins in the media preventing their binding to, and activation of the cell-
bound Tie2 receptor.  However, given that this is a mouse glioma cell line and 
bevacizumab targets only human VEGF, we needed to find a compound that effectively 
targets the mouse VEGF pathway.  We obtained an antibody named DC101 that targets 
mouse VEGFR2 and performed a pilot study to determine if DC101 led to similar 
changes as those observed for VEGF-Trap/aflibercept.   
We implanted GL261 mouse glioma cells intracranially in C57/BL6 mice and treated 
them with either control or DC101 three times a week.  Mice were sacrificed when signs 
of high tumor burden became apparent and brain was extracted, formalin fixed and 
paraffin embedded for morphological studies and protein expression analysis.  Upon 
histological assessment, GL261 tumors were characterized by a well circumscribed 
tumor, with dilated blood vessels and tendency to hemorrhage.  No overt necrosis could 
be appreciated in either group.  Tumors in the control group had a sharp tumor-normal 
brain interface and no signs of invasive nodules.  On the other hand, tumors treated with 
DC101 showed disruption of the interface between tumor and normal brain with finger-
like projections into the normal brain and some areas showing initial detachment from the 
main tumor mass, suggesting early stages of invasion (Figure 23).   
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DC101 treatment leads to decreased microvascular density. Since targeting the 
VEGF-VEGFR pathway disrupts the process of angiogenesis, a way to measure its 
effectiveness is quantifying microvascular proliferation within the tumor.  For this 
purpose, we performed CD31 staining to label endothelial cells and proceeded to quantify 
vascular structures, defined as a cluster of 3 or more endothelial cells having a lumen 
(Figure 24).  To be considered a discrete vascular structure, the lumen cannot connect 
with any other vascular structure within the field.  Our results show a decrease in MVD 
of more than 50% in tumors treated with DC101 versus control treated tumors.  This 
provides evidence that DC101 is effectively inhibiting the process of new vessel 
formation within the tumor.  
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DC101 treatment leads to recruitment of macrophages, Tie2 expressing cells and 
TEMs to the periphery of the tumor. We next determined if treatment with DC101 led 
to macrophage recruitment, as does bevacizumab and aflibercept.  To evaluate this, we 
performed Iba1 staining in tissue sections from mice treated with either control treatment 
or DC101 (Figure 25).   Quantification of Iba1 positive cells revealed a highly significant 
increase in macrophage recruitment to the periphery of the tumor.  As can be observed in 
the image, these cells tend to accumulate right at the interface between tumor and normal 
brain.   
 
Treatment with DC101 leads to Tie2 expressing cell accumulation around the 
periphery of the tumor and TEM recruitment. We have already shown that anti-
VEGF therapy with bevacizumab and aflibercept leads to Tie2 expressing cell 
accumulation around the periphery of the tumor, and in particular TEM recruitment 
around areas of invasion.  To determine if DC101 had a similar effect we performed 
double immunofluorescence staining for Iba1 and Tie2 (Figure 26).  Quantification of 
double positive cells shows a significant increase in the fraction of macrophages 
expressing the Tie2 receptor following treatment with DC101.  Taken together, these data 
confirms that DC101 leads to similar changes in the tumor microenvironment as other 
human anti-VEGF therapeutic approaches and therefore is a sensible model to study the 
effect of macrophage depletion on the responsiveness of tumors to anti-VEGF therapy.  
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GL261sTie2 cell line has similar growth kinetics as the control GL261.GFP cell line. 
Before proceeding to evaluate whether in the presence of sTie2 gliomas responded better 
to anti-VEGF therapy, we wanted to determine if sTie2 expression led to differences in 
tumor growth and survival.  For this purpose we performed a proliferation assay in vitro 
and studied the tumor growth in vivo in C57/BL6 mice (Figure 27).  Cells showed no 
difference in BrdU incorporation in vitro, demonstrating that there is no significant 
difference in their rate of proliferation.  Upon implantation, no differences in tumor size 
or overall survival were observed with the expression of sTie2.  Upon histological 
examination, both GL261.GFP and GL261.sTie2 displayed circumscribed borders with 
no invasion towards adjacent normal brain.  However, GL261.sTie2 had more extensive 
necrotic foci highlighting the importance of an active Ang-Tie2 pathway for the 
formation of vascular structures and tissue oxygenation.  
 
Targeting the Ang-Tie2 pathway does not lead to improved survival in a GL261 
syngeneic glioma model. One of the most important outcome measures in cancer 
treatment is overall survival.  Therefore, we were very interested in evaluating whether 
targeting the Ang-Tie2 pathway in combination with anti-VEGF therapy led to improved 
survival in mice.  Mice were implanted with GL261.GFP or GL261.sTie2 and treated 
with either control treatment or DC101 three times a week for 4 weeks.  Mice were 
sacrificed when signs of high tumor burden and overall survival was evaluated for each 
group (Figure 28).  DC101 treatment alone led to a significant increase in survival when 
compared to control therapy.  Unfortunately, adding sTie2 to the treatment regimen did 
not further increase the overall survival in mice.  There could be several reasons for this. 
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There is a possibility that targeting the Ang-Tie2 pathway does not lead to improved 
survival.  However, because this cell line overexpresses sTie2 from the moment of 
implantation and prior to DC101 treatment administration, it is possible that the cells 
were able to adapt more quickly to DC101 treatment.   
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Targeting the Ang-Tie2 pathwat leads to a significant decrease in the invasive 
phenotype after anti-VEGF therapy. One of the main problems arising from anti-
VEGF therapeutic approaches is the enhancement of invasion observed after therapy.  
This renders surgical excision ineffective, which coupled with the highly resistant nature 
of GBM leaves patients with little to no therapeutic alternatives.  At this point survival is 
measured in weeks.  Therefore, another important outcome measure in this setting is 
preventing the development of invasive feature after anti-angiogenic treatment so that 
surgical excision becomes an option in this patient population.  We were interested in 
evaluating whether targeting the Ang-Tie2 pathway in combination with anti-VEGF 
therapy was effective at achieving this goal.  Mice were implanted with GL261.GFP or 
GL261.sTie2 and treated with either control treatment or DC101 three times a week for 4 
weeks.  Mice were sacrificed when signs of high tumor burden and brains were extracted, 
formalin fixed and paraffin embedded for histological and protein expression analysis.  
Histological analysis of tumor sections revealed a striking increase in the number of 
invasive nodules when DC101 was administered in GL261.GFP derived tumors. In areas 
where no overt invasive nodules could be observed, the tumor-normal brain interface was 
disrupted and finger-like projections into the normal brain became to appear.  There was 
a striking and statistically significant decrease in the number of invasive nodules in 
GL261.sTie2 derived tumors treated with DC101 compared to GL261.GFP derived 
treated tumors.  There were virtually no invasive nodules present and no disruption of the 
tumor-normal brain interface (Figure 29).   
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Targeting the Ang-Tie2 pathway prevents recruitment of TEMs to the tumor 
following anti-VEGF therapy. Our data supports an active role for Ang2 in the 
recruitment and modulation of TEMs which then promote an invasive microenvironment 
conducive for glioma cell invasion into the normal brain.  We wanted to evaluate whether 
targeting the angiopoietins effectively prevented the recruitment of TEMs.  For this 
purpose we obtained tissue sections from GL261.GFP or GL261.sTie2 glioma-bearing 
mice treated with either control or DC101 treatment.  Double staining for Iba1, a 
monocyte/microglia marker, and Tie2 was performed and double positive cells were 
quantified (Figure 30).  Our results show a significant decrease in the number of double 
positive cells, i.e. TEMs, in GL261.sTie2 derived tumors treated with DC101 when 
compared to treated GL261.GFP derived tumors.  This result highlights the importance of 
available Ang2 for the recruitment of these cells and further supports their role in the 
development of invasion following anti-VEGF therapy 
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Conclusions 
 
Targeting the Ang-Tie2 pathway in combination with anti-VEGF therapy leads to an 
impairment in TEM recruitment and a consequent significant decrease in the invasive 
phenotype observed after anti-VEGF therapy.  This has important implications for 
patients for GBM.  By preventing this enhanced invasive phenotype, we can potentially 
render the tumor amenable to surgical excision and this way improve patient survival.  
Infiltration of glioma cells into the normal brain is characteristic of GBM and it is 
important to understand that curative therapy will require the effective targeting of this 
cell population.  However, by removing the bulk of the tumor after anti-VEGF therapy 
we can significantly improve patient survival, one of the main goals in GBM. 
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Chapter VIII: Discussion 
 
 
GB continues to be a devastating disease, with a median survival of only 15 
months despite aggressive chemotherapy.1-2 One of the main features of GBM 
contributing to its highly malignant behavior is its infiltrative nature, which makes 
complete surgical resection virtually impossible.  This, coupled with its highly resistant 
nature, makes GB an incredibly difficult cancer to treat.  
In 2009, bevacizumab, an anti-VEGF antibody, was FDA approved for the 
treatment of recurrent GBM.  Treatment with bevacizumab consistently leads to dramatic 
radiographic responses and improved progression free survival.47 However, despite its 
anti-tumor effects, patients treated with bevacizumab invariably present with recurrent 
disease, and upon recurrence the tumor acquires a highly aggressive phenotype 
characterized by enhanced invasion and resistance to therapy.52-53,56,79,80  Once patients 
present with this stage of disease, there is little to no effective therapy that can be 
offered.80  Furthermore, surgical removal is ineffective due to further enhancement of its 
already infiltrative behavior.  Therefore, understanding the mechanisms behind the 
development of such a malignant disease state will lead to the development of improved 
combined therapeutic approaches that can result in better patient outcomes. 
The results obtained throughout this project implicate the Ang-Tie2 pathway as a 
key player in the recurrence of GBM following anti-VEGF therapy and in particular, the 
acquisition of its highly invasive behavior.  An accumulation of Tie2 expressing cells 
accompanies the development of invasive nodules.  Further characterization of these cells 
demonstrated them to be TEMs.  Shortly after their discovery, TEMs were shown to be 
detectable in the blood of healthy donors, comprising less than 10% of circulating 
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mononuclear cells in these cases. Furthermore, they comprise the main monocytic 
population, other than tumor-associated macrophages, within certain types of solid 
tumors.  Interestingly, their presence is undetectable in non-neoplastic healthy tissue.73 In 
hepatocellular carcinoma (HCC), there is one report correlating the occurrence of TEMs 
in the blood of patients with the presence and recurrence of HCC.74 Taken together, these 
data suggests that TEMs play a role in cancer development and progression, and supports 
the notion that their recruitment following anti-VEGF therapy is an important event 
during recurrence.  There have been reports where accumulation of tumor associated 
macrophages has been linked to anti-angiogenic treatment and correlated with worse 
patient survival.82-83 However, the authors did not further characterize this myeloid 
population and did not follow up on the association.  
MMP9 is shown to be upregulated following anti-VEGF therapy and our data 
shows that TEMs have higher secretion of MMP2 and MMP9 than their Tie2 negative 
counterparts, suggesting that TEMs are at least partially responsible for the upregulation 
of MMP9 following anti-VEGF therapy.  Interestingly, the Tie2 receptor has been shown 
to be necessary for the secretion of MMP9 by TEMs in vitro81, and we gathered data 
showing that Ang2 is capable of further enhancing the secretion of gelatinases by TEMs, 
but had no effect in Tie2 negative monocytes.  Our data strongly supports that TEMs 
have an important role in the invasive phenotype observed after anti-VEGF therapy and 
that targeting this population can prove to be beneficial for patients with recurring GBM. 
Furthermore, our data highlights the potential benefit of inhibiting the Ang-Tie2 pathway 
in the context of anti-VEGF treatment by two distinct mechanisms: 1) TEMs cannot be 
recruited to the tumor due to lack of functionally available Ang2 and, 2) Ang2 is not 
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available to modulate TEMs that might already be present within the tumor and enhance 
their pro-invasive features.   
Ang2 has been shown to promote invasion of cancer cells independent of the 
tumor microenvironment.  Ang2 expression has been correlated with invasion in GBM 
and breast cancer surgical samples, and with distant metastasis in the latter.84-85 In 
glioma, Ang2 was shown to induce MMP2 expression and increase invasion in vitro.  
Furthermore, implantation of U87 glioma cells over-expressing Ang2 led to the 
production of invasive tumors in nude mice, a feature largely absent in U87-derived 
tumors.86 In this study, authors report on the increased expression of MMP2 in vitro and 
in vivo and its contribution to glioma invasion in vitro, but do not characterize the nature 
of the infiltrating myeloid cells so their contribution to the invasive features observed 
under these conditions remains unexplored.  The results obtained in this work provide 
evidence that Ang2-mediated TEM recruitment is at least partially responsible for the 
invasive features observed after anti-VEGF therapy, and potentially of MMP2 
upregulation.  However, several mechanisms are likely to be in place and it is possible 
that inhibition of the effect of angiopoietins, and in particular Ang2, can also have effects 
within the tumor compartment (i.e. cancer cells).  It is worth noting that some of the 
effects of Ang2 have been shown to be mediated by integrins, particularly α5β1, 
suggesting that targeting the ligand would be a better approach than targeting the 
receptor.86-87   
An important limitation to our approach is that by using sTie2 as a means to 
inhibit the Ang-Tie2 pathway, all angiopoietins present within the environment will be 
inhibited, which does not allow us to differentiate between the effect of inhibiting each 
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one individually.  Glioma cells have been shown to express Ang1 which in turn leads to 
chemoresistance through upregulation of ABC transporters.88  ABC transporters are not 
likely to play a role in resistance to bevacizumab since its mechanism of action does not 
require entry into tumor cells.  However, it cannot be ruled out that some of the effects 
observed in the combination treatment group can be caused by inhibition of Ang1 within 
the tumor and tumor vasculature.  We were unable to detect Ang1 in glioma tissue 
sections, independent of treatment status.  Furthermore, research on TEMs has not 
supported a role for Ang1 in their recruitment or modulation, supporting the notion that it 
has little to no role in the invasive phenotype observed after anti-VEGF therapy.77 
However, this cannot be completely ruled out since we have observed activation of Tie2 
with experimentally undetectable levels of Ang1.  Furthermore, the Ang1-Tie2 axis has 
been shown to enhance adhesion of glioma cells to endothelial cells and induce glioma 
cell invasion in vitro.89 
Understanding the mechanisms of resistance to anti-VEGF therapy has been the 
focus of extensive research since its development.  The results depicted throughout this 
project suggest a role for the Ang-Tie2 pathway in the modulation of the tumor 
microenvironment for the development of invasion as a means to escape VEGF blockade 
in gliomas.  Several groups, however, have reported on the role of different signaling 
pathways in the development of resistance to anti-VEGF therapy in gliomas.  For 
example, Carbonell et al. report on the upregulation of integrin β1 following anti-VEGF 
therapy in gliomas and provide evidence that targeting integrin β1 potentiates the effects 
of bevacizumab in a glioma xenograft and inhibit the development of invasion after 
therapy.92  Interestingly, Ang2 has been shown to act through integrins, in particular 
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integrin α5β1, and in gliomas it has been shown to enhance MMP2 expression and 
invasion through interactions with this integrin.86-87  This suggests a potential interplay 
between these two pathways in the recurrent phenotype observed in gliomas. A potential 
mechanism of sTie2 at inhibiting invasion after anti-VEGF therapy could be through 
inhibition of Ang2-mediated activation of α5β1 integrin. 
Another interesting study found an inverse relationship between activation of the 
VEGF/VEGFR pathway and c-met phosphorylation and activation in gliomas.93 They 
provide evidence that VEGF leads to an inhibition of c-met phosphorylation and 
activation and that in the absence of VEGF there is enhanced phosphorylation of this 
receptor within glioma cells.  Furthermore, this increased phosphorylation led to 
enhanced migration of glioma cells in vitro and enhanced vessel cooption in vivo. 
Consequently, they demonstrate enhanced phosphorylation of c-met accompanying 
invasion following VEGF blockade, and successfully inhibit the invasive phenotype 
observed with anti-VEGF monotherapy with the concurrent inhibition of c-met.  
Interestingly, this approach has been shown to be successful at inhibiting invasion and 
metastasis in pre-clinical models of other types of solid tumors.94 These studies, along 
with others associating a multitude of pathways to anti-VEGF therapy resistance, 
highlight the multiplicity of mechanisms used by cancer cells to acquire resistance, and 
potentially argue against the use of highly selective therapy (i.e. targeted therapy).  More 
generalized approaches might be more successful than attempting to target one or several 
pathways within the transformed epithelial compartment.  Targeting the tumor 
microenvironment, for example through immune modulation, can be such an approach. 
 
 93 
Currently, there are several inhibitors of the Ang-Tie2 pathway either under 
development or under pre-clinical or clinical evaluation.  Selectively targeting Ang2 as 
monotherapy has been shown to be effective at inhibiting tumor growth in several solid 
malignancies, including colon carcinoma, renal cell carcinoma, ovarian carcinoma, 
pancreatic carcinoma and breast carcinoma.30,90 Added to this, several studies have 
explored the value of targeting Ang2 in combination with anti-VEGF therapy and have 
shown that the combination therapy has greater anti-tumor effects than either approach 
alone.30,91  Currently, there is no preclinical or clinical data assessing the efficacy of 
targeting the Ang-Tie2 pathway alone or in combination with bevacizumab in glioma.  
We show here that by targeting both, the Ang-Tie2 pathway and the VEGF pathway, we 
are able to circumvent the development of invasion in the GL261 syngeneic glioma 
model.  This has very important implications for GBM patients.  As stated above, the 
enhanced invasive features observed in recurring tumors after anti-VEGF therapy render 
surgical excision ineffective.  By effectively preventing the development of enhanced 
invasion, we could potentially render the tumors amenable to surgical removal upon 
recurrence.  It is important to note that GBM is naturally a highly invasive tumor and 
complete removal of all tumor cells is virtually impossible at any stage of disease.  
Curative therapy will require effectively targeting remaining tumor cells after surgical 
removal of the bulk of the tumor.  Having said this, being able to improve survival in 
patients with GBM is one of the main therapeutic goals and the approach suggested here 
has the potential of doing so.  
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Chapter IX: Future Directions 
Besides upregulation of Ang2, we were also able to see an increase in VEGF 
expression after anti-VEGF therapy.  Interestingly, we detected a dramatic increase in 
binding of VEGF to its receptor within the glioma compartment following bevacizumab 
treatment (Figure 31).  The hypoxic environment that ensues after anti-VEGF therapy 
due to decreased microvascular density is a possible reason for VEGF upregulation in the 
context of anti-VEGF therapy.8 Added to this, certain VEGF isoforms bind the 
extracellular matrix until protease activity releases them making them available to bind 
cell bound receptors.95 The enhanced expression of MMPs observed after anti-VEGF 
therapy can lead to release of ECM-bound VEGF upon ECM degradation, which in turn 
can explain the enhanced binding to its receptor within the tumor compartment.  
Interestingly, VEGF expression has been associated with higher tumor grade in 
gliomas.96 Furthermore, it has been associated with increased invasion and metastasis in 
several solid malignancies.97-98  
The observation of enhanced VEGF binding to its receptor within glioma cells 
might seem counterintuitive in the context of bevacizumab treatment, given the fact that 
we are administering an anti-VEGF antibody that prevents this same interaction.  
However, antibodies (i.e. bevacizumab) generally do not cross an intact blood brain 
barrier99 and although the BBB within gliomas is compromised, vessel abnormalities are 
thought to impede diffusion of chemotherapeutic drugs to the tumor.  Factors such as 
high interstitial pressure and chaotic blood flow lead to uneven drug distribution and lack 
of drug delivery to some areas of the tumor.100-101 In the presence of bevacizumab, some 
of these abnormalities regress, a process called vessel normalization.  Although this 
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process has been shown to improve delivery of chemotherapeutic drugs, in the context of 
GBM vessel normalization is accompanied by restoration of the low permeability 
BBB.102 Our observation suggests that regardless of the status of the vascular network 
within GBM, bevacizumab is generally not able to reach cancer cells in the brain in 
sufficient amounts to cause inhibition outside of the vascular compartment.  Given the 
tight interplay of the VEGF and the Ang-Tie2 pathway in vessel physiology and 
pathology, it would be interesting to explore whether Ang2 can potentiate the effects of 
VEGF-VEGFR activation in gliomas or viceversa.  Furthermore, in a recent publication 
by Niewoehner et al., they report on the development of a modified antibody against β-
amyloid that has facilitated transport through the BBB via transferrin receptor mediated 
transcytocis.103  It would be interesting to apply this technology to anti-VEGF targeted 
approaches in GB to improve delivery to the tumor bed.  
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Finally, we were interested in understanding the mechanisms through which Ang2 
is upregulated following anti-VEGF therapy.  Uncovering the molecular players leading 
to this phenomenon can lead to the identification of other therapeutic targets to be 
combined with anti-VEGF therapy.  The Ets family transcription factors Ets-1 and Elf-1 
have been reported to act as strong enhancers of endothelial cell Ang-2–promoter 
activity.104 In particular, Ets-1 has been shown to strongly induce Ang2 promoter activity 
in cervical cancer cells.105 Furthermore, Ets-1 has been associated with malignancy in 
gliomas and has been shown to promote invasion and migration in glioma cells.106-107 
Therefore, we hypothesized that activation of Ets-1 was responsible for inducing 
expression of Ang2 and enhancing the invasive phenotype of gliomas after anti-
angiogenic treatment. Ras-mediated phosphorylation of Ets1 has been shown to 
contribute to its transactivation.108 We obtained an antibody that recognizes the 
phosphorylated form of Ets-1 to test our hypothesis. We analyzed tumor cell lysates from 
glioma-bearing mice treated with control PBS or bevacizumab for 6 weeks (Figure 32).  
We observed a significant increase in phospho-Ets1 levels, suggesting an increase in its 
transactivation activity as a response to bevacizumab treatment. Future studies on further 
understanding the role of Ets-1 in the regulation of Ang2 within glioma cells, as well as 
its role in the invasive recurrence of gliomas after anti-VEGF therapy can shed light on to 
the molecular events leading to the highly malignant behavior of gliomas following anti-
VEGF therapy. 
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Chapter X:  List of Conclusions 
1) Tie2 expressing cells are recruited to the tumor following anti-VEGF therapy in 
gliomas. 
2) Temozolomide treatment does not lead to recruitment of Tie2 expressing cells. 
3) TEMs are recruited to the tumor following anti-VEGF therapy in gliomas. 
4) TEMs accumulate in the periphery of the tumor and around areas of invasion 
following anti-VEGF therapy. 
5) Temozolomide does not lead to recruitment of TEMs. 
6) Ang2 is upregulated within the tumor after anti-VEGF therapy in gliomas. 
7) Ang2 upregulation after anti-VEGF therapy occurs mainly in the periphery of the 
tumor and around areas of invasion. 
8) Glioma cells significantly increase their expression of Ang2 after anti-VEGF 
therapy. 
9) Temozolomide treatment does not lead to Ang2 upregulation. 
10) THP-1 cells significantly increase their expression of Tie2 when exposed to 
hypoxia in the presence of IL4 and IL13 M2-polarizing cytokines. 
11) Ang2 is chemoattractant to TEMs in vitro and in vivo. 
12) TEMs secrete higher amounts of MMP2 and MMP9 than their Tie2 negative 
counterparts. 
13) MMP9 is upregulated in the tumor following anti-VEGF therapy in gliomas. 
14) TEMs are a source of MMP9 within the tumor following anti-VEGF therapy. 
15) Conditioned media of polarized THP-1 cells induces invasion of glioma cells in 
vitro. 
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16) Conditioned media from Tie2-expressing THP-1 cells induces invasion of glioma 
cells and glioma stem cells in vitro. 
17) Targeting the VEGF receptor leads to a similar invasive pattern as that observed 
for VEGF-Trap/aflibercept and bevacizumab. 
18) Targeting the VEGF receptor leads to a reduction in microvascular density. 
19) Targeting the VEGF receptor leads to macrophage recruitment. 
20) Accumulation of macrophages following anti-VEGFR treatment occurs mainly in 
the peripheral areas. 
21) Targeting the VEGF receptor leads to TEM recruitment. 
22) Accumulation of TEMs after anti-VEGFR treatment occurs mainly around the 
peripheral areas of the tumor. 
23) GL261 mouse glioma cells overexpressing soluble Tie2 produce tumors in vivo. 
24) GL261.sTie2 and GL261.GFP control cells produce non-invasive tumors. 
25) GL261.sTie2 produces more necrotic tumors than GL261.GFP control cells. 
26) Targeting the Ang-Tie2 pathway using a sTie2 in combination with anti-VEGF 
therapy does not lead to improved survival. 
27) Targeting the Ang-Tie2 pathway using sTie2 in combination with anti-VEGF 
therapy leads to decreased invasion. 
28) Targeting the Ang-Tie2 pathway using sTie2 in combination with anti-VEGF 
therapy prevents recruitment of TEMs to the tumor. 
 
 
 
 References 
Figure 33. Role of the Ang-Tie2 pathway in the invasive recurrence of 
therapy. An inititally circumscribed tumor is exposed to an agent targeting the VEGF pathway.  This leads to 
vessel regression and hypoxia, causing an increase in the expression of VEGF.  Through mechanisms not yet 
identified, Ang2 is upregulated within glioma cells.  Ang2 upregulation leads to recruitment of Tie2
cells, and TEMs in particular.  TEMs secrete high amoun
activity is further enhanced by Ang2. This leads to  degradation of the extracellular matrix providing a pathway 
for tumor cell migration and invasion into adjacent structures. The driving forces behind g
and invasion remain obscure. 
101 
 
 
 
 
glioblastoma
ts of pro-invasive molecules such as MMPs, and this 
 following anti-VEGF 
-expressing 
lioma cell migration 
 102 
1)  Dolecek, TA., Propp, JM., Stroup, NE., Kruchko, C. (2012) CBTRUS statistical 
report: primary brain and central nervous system tumors diagnosed in the United 
States from 2005-2009. Neuro Oncol, 14, Suppl 5, v1-49. 
2) Van Meir, EG., Hadjipanayis, CG., Norden, AG., Shu, HK., Wen. PY., Olson, JJ. 
(2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant 
glioma. CA Cancer J Clin, 60(3), 166-193. 
3) Wen, PY., Kesari, S. (2008) Malignant gliomas in adults. NEJM, 359(5), 492-507. 
4) Das, S., Marsden, PA. (2013) Angiogenesis in Glioblastoma. NEJM, 369(16), 1561-
1563. 
5) Kreisl, TN., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, 
M., Butman, JA., Camphausen, K., Park, J., Albert, PS., Fine, HA. (2009) Phase II 
trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor 
progression in recurrent glioblastoma. J Clin Oncol, 27(5), 740-745. 
6) Friedman, HS., Prados, MD., Wen, PY., Mikkelsen, T., Schiff, D., Abrey, LE., Yung, 
WK., Paleologos, N., Nicholas, MK., Jensen, R., Vredenburgh, J., Huang, J., Zheng, 
M., Cloughesy, T. (2009) Bevacizumab alone and in combination with irinotecan in 
recurrent glioblastoma. J Clin Oncol, 27(28), 4733-4740. 
7) Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature, 438(15), 
932-936. 
8) Carmeliet, P. (2003) Angiogenesis in health and disease. Nat Med, 9(6), 653-660. 
9) Senger, D. R., Galli, S. J., Dvorak, M. (1983) Tumor cells secrete a vascular 
permeability factor that promotes accumulation of ascites fluid. Science 219, 983–
985. 
 103 
10) Leung, DW., Cachianes, G., Kuang, WJ., Goeddel, DV., Ferrara, N. (1989) Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science, 246, 1306-1309. 
11) Keck, PJ., Hauser, SD., Krivi, G., Sanzo, K., Warren, T., Feder, J., Connolly, DT. 
(1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. 
Science, 246, 1309-1312.   
12) Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, JC., 
Abraham, JA. (1991) The human gene for vascular endothelial growth factor. 
Multiple protein forms are encoded through alternative exon splicing. J Bio Chem, 
266, 11947-11954. 
13) Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. (1991) The vascular 
endothelial growth factor family: identification of a fourth molecular species and 
characterization of alternative splicing of RNA. Mol Endocrinol, 5,1806–1814. 
14) Millauer, B., Wiziqmann-Voos, S., Schnϋrch, H., Martinez, R., Møller, NP, Risau, 
W., Ullrich, A. (1993) High affinity VEGF binding and developmental expression 
suggest Flk1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72(6), 
835-846. 
15) Kowanetz, M., Ferrara, N. (2006) Vascular endothelial growth factor signaling 
pathways: Therapeutic implications. Clin Can Res, 12(17), 5018-5022. 
16) Carmeliet, P., Jain, RK. (2011) Molecular mechanisms and clinical applications of 
angiogenesis. Nature, 473(7347), 298-307. 
17) Dumont, DJ., Gradwohl, GJ., Fong, GH., Auerbach, R., Breitman, ML. (1993) The 
endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of 
receptors. Oncogene, 8(5), 1293-1301. 
 104 
18) Davis S., Aldrich TH., Jones PF., Acheson, A, Compton, DL., Jain, V., Ryan, TE., 
Bruno, J., Radziejewski, C., Maisonpierre, PC., Yancopoulos, GD. (1996). Isolation 
of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression 
cloning. Cell, 87, 1161-1169.  
19) Maisonpierre PC., Suri C., Jones PF., Bartunkova, S., Wiegand, SJ., Radziejewski, 
C., Compton, D., McClain, J., Aldrich, TH., Papadopoulos, N., Daly, TJ., Davis, S., 
Sato, TN., Yancopoulos, GD. (1997). Angiopoietin-2, a natural antagonist for Tie2 
that disrupts in vivo angiogenesis. Science, 277, 55-60.  
20) Valenzuela DM., Griffiths JA., Rojas J., Aldrich, TH., Jones, PF., Zhou, H., McClain, 
J., Copeland, NG., Gilbert, DJ., Jenkins, NA., Huang, T., Papadopoulos, N., 
Maisonpierre, PC., Davis, S., Yancopoulos, GD. (1999). Angiopoietins 3 and 4: 
diverging gene counterparts in mice and humans. Proc. Natl. Acad. Sci., 96, 1904-
1909. 
21) Dumont DJ., Gradwohl G., Fong GH., Puri, MC., Gertsenstein, M., Auerbach, A., 
Breitman, ML. (1994) Dominant-negative and targeted null mutations in the 
endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the 
embryo. Genes Dev, 8(16), 1897-1909. 
22) Sato TN., Tozawa Y., Deutsch U., Wolburg-Buchholz, K., Fujiwara, Y, Gendron-
Maguire, M., Gridley, T., Wolburg, H., Risau, W., Qin, Y. (1995). Distinct roles of 
the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 376, 
70-74. 
 105 
23) Suri, C., McClain, J., Thurston, G., McDonald, DM., Shou, H., Oldmixon, EH., Sato, 
TN., Yancopoulos, GD. (1998) Increased  vascularization in mice overexpressing 
angiopoietin-1. Science, 282(), 468-471. 
24) Thurston, G., Suri, C., Smith, K., McClain, J., Sato, TN., Yancopoulos, GD., 
McDonald, DM. (1999) Leakage-resistant blood vessels in mice transgenically 
overexpressing angiopoietin-1. Science, 286(5449), 2511-2514. 
25) Suri C., Jones PF., Patan S., Bartunkova, S., Maisonpierre, PC., Davis, S., Sato, TN., 
Yancopoulos, GD. (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 
receptor, during embryonic angiogenesis. Cell, 87, 1171-1180. 
26) Matilde, T., Agrawal, DK. (2008) Intra and extravascular transmembrane signaling of 
angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med, 12(3), 810-828. 
27) Reiss, Y., Droste, J., Heil, M., Tribulova, S., Schmidt, MH., Schaper, W., Dumont, 
DJ., Plate, KH. (2007) Angiopoietin-2 impairs revascularization after limb ischemia. 
Circ Res, 101(1), 88-96. 
28) Lobov, IB., Brooks, PC., Lang, RA. (2002) Angiopoietin-2 displays VEGF-
dependent modulation of capillary structure and endothelial cell survival in vivo. 
PNAS, 99(17), 11205-11210. 
29) Yuan, HT., Khankin, EV., Karumanchi, SA., Parikh, SM. (2009) Angiopoietin 2 is a 
partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Bio, 29(8), 
2011-2022. 
30) Daly, C., Eichten, A., Castanaro, C., Pasnikowski, E., Adler, A., Lalani, AS., 
Papadopoulos, N., Kyle, AH., Minchinton, AI., Yancopoulos, GD., Thurston, G. 
 106 
(2013) Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits 
the effects of VEGF inhibition. Cancer Res, 73(1), 108-118. 
31) Gale, NW., Thurston, G., Hackett, SF., Renard, R., Wang, Q., McClain, J., Martin, 
C., Witte, C., Witte, MH., Jackson, D., Suri, C., Campochiaro, PA., Wiegand, SJ., 
Yancopoulos, GD. (2002) Angiopoietin-2 is required for postnatal angiogenesis and 
lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell, 
3(3), 411-423. 
32) Fiedler, U., Reiss, Y., Scharpfenecker M., Grunow, V., Koidl, S., Thurston, G., Gale, 
NW., Witzenrath, M., Rosseau, S., Suttorp. N., Sobke, A., Hermann, M., Preissner, 
KT. (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial 
role in the induction of inflammation. Nat Med, 12(2), 235-239. 
33) Arai, F., Hirao, A., Ohmura, M., Sato, H., Matsuoka, S., Takubo, K., Ito, K., Koh, 
GY., Suda, T. (2004) Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell 
quiescence in the bone marrow niche. Cell, 118(2), 149-161. 
34) Valable, S., Bellail, A., Lesne,S., Liot, G., Mackenzie, ET., Vivien, D., Bernaudin, 
M., Petit, E. (2003) Angiopoietin-1-induced PI3-kinase activation prevents neuronal 
apoptosis. FASEB J, 17(3), 443-445. 
35) Carmeliet P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., 
Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt. C., Declercq, C., Pawling, J., 
Moons, L., Collen, D., Risau, W., Nagy, A. (1996) Abnormal blood vessel 
development and lethality in embryos lacking a single VEGF allele. Nature, 
380(6573), 435-439. 
 107 
36) Hanahan, D., Folkman, J. (1996) Patterns and emerging mechanisms of the 
angiogenic switch during tumorigenesis. Cell, 86(3), 353-364. 
37) Ribatti, D., Vacca, A., Dammacco, F. (1999)  The role of the vascular phase in solid 
tumor growth: A historical review. Neoplasia, 1(4), 293-302. 
38) Bergers, G., Benjamin, LE. (2002) Tumorigenesis and the angiogenic switch. Nat Rev 
Can, 3, 401-410. 
39) Harach, HR., Franssila, KO., Wasenius, VM. (1985) Occult papillary carcinoma of 
the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer, 
56(3), 531-538. 
40) Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., 
Heissig, B., Marks, W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., HackettNR., Crystal, 
RG., Moore, MA., Hajjar, KA., Manova, K., Benezra, R., Rafii, S. (2001) Impaired 
recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells 
blocks tumor angiogenesis and growth. Nat Med, 7(11), 1194-1201. 
41) Maniotis, AJ., Folberg, R., Hess, A., Seftor, EA., Gardner, LM., Pe’er, J., Trent, JM., 
Meltzer, PS., Hendrix, MJ. (1999) Vascular channel formation by human melanoma 
cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol, 155(3), 739-752. 
42) Benjamin, LE., Golijanin, D., Itin, A., Pode, D., Keshet, E. (1999) Selective ablation 
of immature blood vessels in established human tumors follows vascular endothelial 
growth factor withdrawal. J Clin Inv, 103(2), 159-165. 
43) Folkman, J. (1971) Tumor angiogenesis. Therapeutic implications. NEJM, 285(21), 
1182-1186. 
 108 
44) Kim, KJ., Li, B., Houck, K., Winer, J., Ferrara, N. (1992) The vascular endothelial 
growth factor proteins: identification of biologically relevant regions by neutralizing 
monoclonal antibodies. Growth Factors, 7(1), 53-64. 
45) Kim, KJ., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, HS., Ferrara, N. (1993) 
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses 
tumour growth in vivo. Nature, 362(6423), 841-844. 
46) Adamis, AP., Shima, DT., Tolentino, MJ., Gragoudas, ES., Ferrara, N., Folkman, J., 
D’Amore, PA., Miller, JW. (1996) Inhibition of vascular endothelial growth factor 
prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. 
Arch Ophtalmol, 114(1), 66-71. 
47) De Bandt, M., Ben Mahdi, MH., Ollivier, V., Grossin, M., Dupuis, M., Gaudry, M., 
Bohlen, P., Lipson, KE., Rice, A., Wu, Y., Gougerot-Pocidalo, MA., Pasquier, C. 
(2003) Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not 
VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J 
Immunol, 171(9), 4853-4859. 
48) Presta, LG., Chen, H., O’Connor, SJ., Chisholm, V., Meng, YG., Krummen, L., 
Winkler, M., Ferrara, N. (1997) Humanization of an anti-vascular endothelial growth 
factor monoclonal antibody for the therapy of solid tumors and other disorders. 
Cancer Res, 57(20), 4593-4599. 
49) Yang, JC., Haworth, L., Sherry, RM., Hwu, P., Schwartzentruber, DJ., Topalian, SL., 
Steinberg, SM., Chen, HX., Rosenberg, SA. (2003) A randomized trial 
of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic 
renal cancer. NEJM, 349(5), 427-434. 
 109 
50) Stark-Vance, V. (2005) Bevacizumab and CPT-11 in the treatment of relapsed 
malignant glioma. Neuro Oncol, 7(3), 279-402 (Abstract #342). 
51) Iwamoto, FM., Fine, HA. (2010) Bevacizumab for malignant gliomas. Arch Neurol, 
67(3), 285-288. 
52) Chinot, OL., Wick, W., Mason, W., Henrikkson, R., Saran, F., Nishikawa, R., 
Carpentier, AF., Hoang-Xuan, K., Kavan, P., Cernea, D., Brandess, AA., Hilton, M., 
Abrey, L., Cloughesy, T. (2014) Bevacizumab plus radiotherapy-temozolomide for 
newly diagnosed glioblastoma. NEJM, 370(8), 709-722. 
53) Gilbert, MR., Dignam, JJ., Armstrong, TS., Wefel, JS., Blumenthal, DT., Vogelbaum, 
MA., Colman, H., Chakravarti, A., Pugh, S., Won, M., Jeraj, R., Brown, PD., Jaeckle, 
KA., Schiff, D., Stieber, VW, Brachman, DG., Werner-Wasik, M., Tremont-Lukats, 
IW., Sulman, EP., Aldape, KD., Curran, WJ Jr., Mehta, MP. (2014) A randomized 
trial of bevacizumab for newly diagnosed glioblastoma. NEJM, 370(8), 699-708. 
54) Rubenstein, JL., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, DF., Shuman, 
MA. (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but 
results in increased vascular cooption. Neoplasia, 2(4), 306-314. 
55) Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, 
M., Bergers, G., Hanahan, D., Casanovas, O. (2009) Antiangiogenic therapy elicits 
malignant progression of tumors to increased local invasion and distant metastasis. 
Cancer Cell, 15(3), 220-231. 
56) deGroot, JF., Fuller, G., Kumar, AJ., Piao, Y., Eterovic, K., Ji, Y., Conrad, CA. 
(2010) Tumor invasion after treatment of glioblastoma with bevacizumab: 
 110 
radiographic and pathologic correlation in humans and mice. Neuro-Oncol, 12(3), 
233-242. 
57) Hanahan, D., Weinberg, RA. (2000) The hallmarks of cancer. Cell, 100(1), 57-70. 
58) Hanahan, D., Coussens, LM. (2012) Accessories to the crime: functions of cells 
recruited to the tumor microenvironment. Cancer Cell, 21(3), 309-322. 
59) Biswas, SK., Mantovani, A. (2010) Macrophage plasticity and interaction with 
lymphocyte subsets: cancer as a paradigm. Nat Immunol, 11(10), 889-896. 
60) Stein, M., Keshav, S., Harris, N., Gordon, S. (1992) Interleukin 4 potently enhances 
murine macrophage mannose receptor activity: a marker of alternative immunologic 
macrophage activation. J. Exp. Med. 176(1), 287–292. 
61) Goerdt, S., Orfanos, CE. (1999) Other functions, other genes: Alternative activation 
of antigen-presenting cells. Immunity, 10(2), 137-142. 
62) Leek, RD., Lewis, CE., Whitehouse, R., Greenall, M., Clark, J., Harris, AL. (1996) 
Association of macrophage infiltration with angiogenesis and prognosis in invasive 
breast carcinoma. Cancer Res, 56(20), 4625-4629. 
63) Lissbrant, IF., Stattin, P., Wikstrom, P., Damber, JE., Egevad, L., Bergh, A. (2000) 
Tumor associated macrophages in human prostate cancer: relation to 
clinicopathological variables and survival. Int J Oncol, 17(3), 445-451. 
64) Fujimoto, J., Sakaguchi, H., Aoki, I., Tamaya, T. (2000) Clinical implications of 
expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer 
Res, 60(10), 2632-2635. 
 111 
65) Hanada, T., Nakagawa, M., Emoto, A., Nomura, T., Nasu, N., Nomura, Y. (2000) 
Prognostic value of tumor-associated macrophage count in human bladder cancer. Int 
J Urol, 7(7), 263-269. 
66) Rossi, ML., Jones, NR., Candy, E., Nicoll, JA., Compton, JS., Hughes, JT., Esiri, 
MM., Moss, TH., Cruz-Sanchez, FF., Coakham, HB. (1989) The mononuclear cell 
infiltrate compared with survival in high-grade astrocytomas. Acta Neuropathol, 
78(2), 189-193. 
67) Nishie, A., Ono, M., Shono, T., Fukushi, J., Otsubo, M., Onoue, H., Ito, Y., Inamura, 
T., Ikezaki, K., Fukui, M., Iwaki, T., Kuwano, M. (1999) Macrophage infiltration and 
heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin 
Can Res, 5(5), 1107-1113. 
68) Hussain, SF., Yang, D., Suki, D., Aldape, K., Grimm, E., Heimberger, AB. (2006) 
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor 
immune responses. Neuro Oncol, 8(3), 261-279. 
69) Komohara, Y., Ohnishi, K., Kuratsu, J., Takeya, M. (2008) Possible involvement of 
the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J 
Pathol, 216(1), 15-24. 
70) Kostianovsky, AM., Maier, LM., Anderson, RC.,  Bruce, JN., Anderson, DE. (2008) 
Astrocytic regulation of human monocytic/microglial activation. J Immunol, 181(8), 
5425-5432. 
71) De Palma, M., Venneri, MA., Galli, R., Sergi Sergi, L., Politi, LS., Sampaolesi, M., 
Naldini, L. (2005) Tie2 identifies a hematopoietic lineage of proangiogenic 
 112 
monocytes required for tumor vessel formation and a mesenchymal population of 
pericyte progenitors. Cancer Cell, 8(3), 211-226. 
72) Venneri, MA., De Palma, M., Ponzoni, M., Pucci, F., Scielzo, C., Zonari, E., 
Mazzieri, R., Doglioni, C., Naldini, L. (2007) Identification of proangiogenic TIE2-
expressing monocytes (TEMs) in human peripheral blood and cancer. Blood, 109(12), 
5276-5285. 
73) Matsubara, T., Kanto, T., Kuroda, S., Yoshio, S., Higashitani, K., Kakita, N., 
Miyazaki, M., Sakakibara, M., Hiramatsu, M., Kasahara, A., Tomimaru, Y., 
Tomokuni, A., Nagano, H., Hayashi, N., Takehara, T. (2013) TIE2-expressing 
monocytes as a diagnostic marker for hepatocellular carcinoma correlates with 
angiogenesis. Hepatology, 57(4), 1416-1425. 
74) De Palma, M., Mazzieri, R., Politi, LS., Pucci, F., Zonari, E., Sitia, G., Mazzoleni, S., 
Moi, D., Venneri, MA., Indraccolo, S., Falini, A., Guidotti, LG., Galli, R., Naldini, L. 
(2008) Tumor-targeted interferon-alpha delivery by Tie2-
expressing monocytes inhibits tumor growth and metastasis. Cancer Cell, 14(4), 299-
311. 
75) Pucci, F., Venneri, MA., Biziato, D., Nonis, A., Moi, D., Sica, A., Di Serio, C., 
Naldini, L., De Palma, M. (2009) A distinguishing gene signature shared by tumor-
infiltrating Tie2-expressing monocytes, blood "resident"monocytes, and embryonic 
macrophages suggests common functions and developmental relationships. Blood, 
114(4), 901-914. 
76) Coffelt, SB., Tal, AO., Scholz, A., De Palma, M., Patel, S., Urbich, C., Biswas, SK., 
Murdoch, C., Plate, KH., Reiss, Y., Lewis, CE. (2010) Angiopoietin-2 regulates gene 
 113 
expression in TIE2-expressing monocytes and augments their inherent proangiogenic 
functions. Cancer Res, 70(13), 5270-5280. 
77) Coffelt, SB., Chen, YY., Muthana, M., Welford, AF., Tal, AO., Scholz, A., Plate, 
KH., Reiss, Y., Murdoch, C., De Palma, M,  Lewis, CE. (2011) Angiopoietin 2 
stimulates TIE2-expressing monocytes to suppress T cell activation and to promote 
regulatory T cell expansion. J Immunol, 186(7), 4183-4190. 
78) Guo, P., Imanishi, Y., Cackowski, FC., Jarzynka, MJ., Tao, HQ., Nishikawa, R., 
Hirose, T., Hu, B., Cheng, SY. (2005) Up-regulation of angiopoietin-2, matrix 
metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 
correlates with the invasiveness of human glioma. 
79) Hu, B., Jarzynka, MJ., Guo, P., Imanishi, Y., Schlaepfer, DD., Cheng, SY. (2006) 
Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 
expression through the alphavbeta1 integrin and focal adhesion kinase signaling 
pathway. Cancer Res, 66(2), 775-783. 
80) Holash, J., Davis, S., Papadopoulos, N., Croll, SD., Ho, L., Russell, M., Boland, P., 
Leidich, R., Hylton, D., Burova, E., Joffe, E., Huang, T., Radziejewski, C., Bailey, 
K., Fandl, JP., Daly, T., Wiegand, SJ., Yancopoulos, GD., Rudge, JS. (2002) VEGF 
Trap: A VEGF blocker with potent anti-tumor effects. PNAS, 99(17), 11393-11398. 
81) Norden, AD., Young, GS., Setayesh, K., Muzikansky, A., Klufas, R., Ross, GL., 
Ciampa, AS., Ebbeling, LG., Levy, B., Drappatz, J., Kesari, S., Wen, PY. (2008) 
Bevacizumab for recurrent malignant gliomas: radiographic and pathological 
correlation in humans and mice. Neurology, 70(10), 779-787.  
 114 
82) Iwamoto, FM., Abrey, LE., Beal K., Gutin, PH., Rosenblum, MK., Reuter, VE., 
DeAngelis, LM., Lassman, AB.  (2009) Patterns of relapse and prognosis 
after bevacizumab failure in recurrent glioblastoma. Neurology, 73(15), 1200-1206. 
83) De Groot, JF., Piao, Y., Tran, H., Gilbert, M., Wu, HK., Liu, J., Bekele, BN., 
Cloughesy, T., Mehta, M., Robins, HI., Lassman, A., DeAngelis, L., Camphausen, 
K., Chen, A., Yung, WK., Prados, M., Wen, PY., Heymach, JV. (2011) Myeloid 
biomarkers associated with glioblastoma response to anti-VEGF therapy with 
aflibercept. Clin Can Res, 17(14), 4872-4881. 
84) Lu-Emerson, C., Snuderl, M., Kirkpatrick, ND., Goveia, J., Davidson, C., Huang, Y., 
Riedemann, L., Taylor, J., Ivy, P., Duda, DG., Ancukiewicz, M., Plotkin, SR., Chi, 
AS., Gerstner, ER., Eichler, AF., Dietrich, J., Stemmer-Rachamimov, AO., Batchelor, 
TT., Jain, RK. (2013) Increase in tumor-associated macrophages after antiangiogenic 
therapy is associated with poor survival among patients with recurrent glioblastoma. 
Neuro Oncol, 15(8), 1079-1087. 
85) Gabrusiewicz, K., Liu, D., Cortes-Santiago, N., Hossain, MB., Conrad, CA., Aldape, 
KD., Fuller, GN., Marini, FC., Alonso, MM., Idoate, MA., Gilbert, MR., Fueyo, J., 
Gomez-Manzano, C. (2014) Anti-vascular endothelial growth factor therapy-induced 
glioma invasion is associated with accumulation of Tie2-expressing monocytes. 
Oncotarget, 5(8), 2208-2220. 
86) Sfiligoi, C., de Luca, A., Cascone, I., Sorbello, V., Fuso, L., Ponzone, R., Biglia, N., 
Audero, E., Arisio, R., Bussolino, F., Sismondi, P., De Bortoli, M. (2003) 
Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and 
short survival. Int J Cancer, 103(4), 466-474. 
 115 
87) Imanishi, Y., Hu, B., Jarzynka, MJ., Guo, P., Elishaev, E., Bar-Joseph, I., Cheng, SY. 
(2007) Angiopoietin-2 stimulates breast cancer metastasis through the 
alpha(5)beta(1) integrin-mediated pathway. Cancer Res, 67(9), 4254-4263. 
88) Martin, V., Xu, J., Pabbisetty, SK., Alonso, MM., Liu, D., Lee, OH., Gumin, J., Bhat, 
KP., Colman, H., Lang, FF., Fueyo, J., Gomez-Manzano, C. (2009) Tie2-mediated 
multidrug resistance in malignant gliomas is associated with upregulation of ABC 
transporters. Oncogene, 28(24), 2358-2363.  
89) Liu, D., Martin, V., Fueyo, J., Lee, OH., Xu, J., Cortes-Santiago, N., Alonso, MM., 
Aldape, K., Colman, H., Gomez-Manzano, C. (2010) Tie2/TEK modulates the 
interaction of glioma and brain tumor stem cells with endothelial cells and promotes 
an invasive phenotype. Oncotarget, 1(8), 700-709. 
90) Leow, CC., Coffman, K., Inigo, I., Breen, S., Czapiga, M., Soukharev, S., Gingles, 
N., Peterson, N., Fazenbaker, C., Woods, R., Jallal, B., Ricketts, SA., Lavallee, T., 
Coats, S., Chang, Y. (2012) MEDI3617, a human anti-angiopoietin 2 
monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor 
xenograft models. Int J Oncol, 40(5), 1321-1330. 
91) Hashizume, H., Falcon, BL., Kuroda, T., Baluk, P., Coxon, A., Yu, D., Bready, JV., 
Oliner, JD., McDonald, DM. (2010) Complementary actions of inhibitors of 
angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res, 70(6), 
2213-2223. 
92) Shawn Carbonell, W., DeLay, M., Jahangiri, A., Park, CC., Aghi, MK. (2013) β1 
integrin targeting potentiates antiangiogenic therapy and inhibits the growth of 
bevacizumab-resistant glioblastoma. Cancer Res, 73, 3145-3154. 
 116 
93) Lou, KV., Chang, JP., Parachoniak, A., Pandika, MM., Aghi, MK., Meyronet, D., 
Isachenko, N., Fouse, SD., Phillips, JJ., Cheresh, DA., Park, M., Bergers, G. (2012) 
VEGF inhibits tumor cell invasion and mesenchymal transition through a 
MET/VEGFR2 complex. Cancer Cell, 22, 21-35. 
94) Sennino, B., Ishiguro-Oonuma, T., Schriver, BJ., Christensen, JG., McDonald, DM. 
(2013) Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic 
mice. Cancer Res, 73, 3692-3703. 
95) Houck, KA., Leung, DW., Rowland, AM., Winer, J., Ferrara, N. (1992) Dual 
regulation of vascular endothelial growth factor bioavailability by genetic and 
proteolytic mechanisms. J Bio Chem, 267(36), 26031-26037. 
96) Lamszus, K., Ulbricht, U., Matschke, J., Brockmann, MA., Fillbrandt, R., Westphal, 
M. (2003) Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in 
astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Can 
Res, 9(4), 1399-1405. 
97) Takahashi, Y., Kitadai, Y., Bucana, CD., Cleary, KR., Ellis, LM. (1995) Expression 
of Vascular Endothelial Growth Factor and Its Receptor, KDR, Correlates with 
Vascularity, Metastasis, and Proliferation of Human Colon Cancer. Cancer Res, 
55(18), 3964-3968. 
98) Decio, A., Taraboletti, G., Patton, V., Alzani, R., Perego, P., Fruscio, R., 
Jürgensmeier, JM., Giavazzi, R., Belotti, D. (2014) Vascular endothelial growth 
factor c promotes ovarian carcinoma progression through paracrine and autocrine 
mechanisms. Am J Pathol, 184(4), 1050-1061. 
 117 
99) Poduslo, JF., Curran, GL., Berg, CT. (1994) Macromolecular permeability across the 
blood-nerve and blood-brain barriers. PNAS, 91(12), 5705-5709. 
100) Dvorak, HF., Nagy, JA., Dvorak, JT., Dvorak, AM. (1988) Identification and 
characterization of the blood vessels of solid tumors that are leaky to circulating 
macromolecules. Am J Pathol, 133(1), 95-109. 
101) Lankelma, J., Dekker, H., Lugue, FR., Luykx, F., Hoekman, K., van der Valk, P., 
van Diest, PJ., Pinedo, HM. (1999) Doxorubicin gradients in human breast cancer. 
Clin Cancer Res, 5(7), 1703-1707. 
102) Thompson, EM., Frenkel, EP., Neuwelt, EA. (2011) The paradoxical effect 
of bevacizumab in the therapy of malignant gliomas. Neurology, 76(1), 87-93. 
103) Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, 
P., Strackle, JO., Lau, W., Tissot, AC., Loetscher, H., Ghosh, A., Freskgård, PO. 
(2014) Increased Brain Penetration and Potency of a Therapeutic Antibody Using a 
Monovalent Molecular Shuttle. Neuron, 81(1), 49-60. 
104) Hegen A., Koidl, S., Weindel, K., Marme, D., Augustin, HG., Fiedler, U. (2004) 
Expression of angiopoietin-2 in endothelial cells is controlled by positive and 
negative regulatory promoter elements. Arterioscler Thromb Vasc Biol, 24(10), 1803-
1809. 
105) Simon, MP., Tournaire, R., Pouyssegur, J. (2008) The angiopoietin-2 gene of 
endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first 
intron and by the central factors GATA-2 and Ets-1. J Cell Physiol, 217(3), 809-818. 
 118 
106) Kitange, G., Kishikawa, M., Nakayama, T., Naito, S., Iseki, M., Shibata, S. 
(1999) Expression of the Ets-1 proto-oncogene correlates with malignant potential in 
human astrocytic tumors. Mod Pathol, 12(6), 618-626. 
107) Sahin, A., Vercamer, C., Kaminski, A. (2009) Dominant-negative inhibition of 
Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and 
reveals differentially expressed Ets 1 target genes. Int J Oncol, 34(2), 377-389. 
108) Nelson, ML., Kang, HS., Lee, GM., Blaszczak, AG., Lau, DK., McIntosh, LP., 
Graves, BJ. (2010) Ras signaling requires dynamic properties of Ets1 for 
phosphorylation-enhanced binding to coactivator CBP. PNAS, 107(22), 10026-10031. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
Vita 
Nahir Cortés Santiago was born in Ponce, Puerto Rico on October 3, 1982, and raised by 
her parents Ivette Santiago Cuevas and Jose Rafael Cortés Soto. Her passion for the 
biological world began as a child and after graduating from Academia Santo Tomás de 
Aquino, Nahir attended The University of Puerto Rico, Mayagüez Campus in Mayagüez, 
Puerto Rico. She graduated with a Bachelor in Biology and entered the University of 
Puerto Rico Medical Sciences Campus in Río Piedras, Puerto Rico where she completed 
her degree of Doctor in Medicine. During the third year of medical school, Nahir 
pondered the possibility of continuing her studies and pursuing a degree of Doctor in 
Philosophy. During her fourth year of medical school, she spent four months doing 
research at the University of Texas – Graduate School of Biomedical Sciences studying 
the role of the Src family of tyrosine kinases in the resistance of prostate cancer to taxane 
therapy under the tutelage of Dr. Gary Gallick.  During these four months, Nahir 
confirmed her interest in research and applied for admission to The University of Texas – 
Graduate School of Biomedical Sciences where she was admitted in May, 2009.  She 
joined the laboratory of Dr. Gomez-Manzano to investigate the mechanisms of resistance 
of gliomas to anti-VEGF therapy in January, 2010. Nahir has been awarded with the 
Rosalie B. Hite Fellowship, which has paid her stipend for three consecutive years.  She 
was also awarded the Minority Scholar in Cancer Research Award by the American 
Association for Cancer Research, which allowed her to assist and participate in the 
AACR Special Conference in Tumor Invasion and Metastasis held in San Diego, 
California in January, 2013.  Starting July 1st, 2014, Nahir will begin a residency in 
Anatomic and Clinical Pathology at Baylor College of Medicine in Houston, Texas. 
